

CURRICULUM VITAE
School of Medicine Faculty

Date: May 11, 2022

PERSONAL INFORMATION

Name: Roslyn Bernstein Mannon
Citizenship: United States

Home Address: 1324 S 83rd Street
Omaha, NE 68124
Phone: (205) 999-7362

RANK/TITLE Professor of Medicine with Tenure
Professor, Pathology and Microbiology
Associate Chief of Research, Division of Nephrology
Vice Chair, Academic Development and Research Mentoring

Business Address: 983040 Nebraska Medical Center
MSB 5569
Omaha, NE 68198-3040

Phone: (402) 559-9239
FAX: (402) 559-9504

HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS:

02/01/2020 Staff Physician, Division of Nephrology, Medical Service
VA Nebraska Western Iowa Health Care System, Omaha, NE

PROFESSIONAL CONSULTANTSHIPS: Not applicable

EDUCATION:

Year	Degree	Institution
9/1977-5/1981	B.A., Biology	The Johns Hopkins University, Baltimore, MD
5/1981-5/1985	M.D.	Duke University School of Medicine, Durham, NC

MILITARY SERVICE: Not applicable

LICENSURE:

1/1987	State of North Carolina - License #31961
3/2003	State of Maryland – License #D0060047 (inactive)
05/29/08	State of Alabama—License #MD 28905
01/02/2020	State of Nebraska—License #32303

BOARD CERTIFICATION:

4/1984	Part 2-National Board of Medical Examiners #320217
6/1985	Part 1- National Board of Medical Examiners #320217
3/1986	Part 3- National Board of Medical Examiners #320217
9/1988	Diplomat of the American Board of Internal Medicine, #119689

11/1992	Subspecialty Certification—Nephrology, #119689
11/2002	Recertification—Nephrology, #119689
11/2012	Recertification—Nephrology #119689

POSTDOCTORAL TRAINING:

Year	Degree	Institution
6/1985-6/1986	Internship, Internal Medicine	Duke Medical Center, Durham, NC
7/1986-6/1988	Residency, Internal Medicine	Duke Medical Center, Durham, NC
7/1988-6/1990	Fellow in Nephrology	Duke Medical Center, Durham, NC
6/1990-6/1991	Chief Resident, Department of Medicine	Duke Medical Center, Durham, NC

ACADEMIC APPOINTMENTS: (In reverse chronological order)

Year	Rank/Title	Institution
02/01/2020	Professor of Medicine (with Tenure),	University of Nebraska Medical Center Omaha, NE
02/01/2020	Professor of Pathology and Microbiology	University of Nebraska Medical Center Omaha, NE
04/10/2019	Robin Luke Professor of Nephrology	University of Alabama at Birmingham Birmingham AL
10/01/2018	Section Chief, Transplant Nephrology	University of Alabama at Birmingham Birmingham AL
11/01/2017	Interim Section Chief, Transplant Nephrology	University of Alabama at Birmingham Birmingham AL
11/06/2015	Endowed Chair in Transplant Clinical Research	University of Alabama at Birmingham Birmingham, AL
3/1/2012-	Director of Research	Comprehensive Transplant Institute Birmingham, AL
06/2012	Senior Scientist, Comprehensive Arthritis, Musculoskeletal and Automimmunity Center (CAMAC)	University of Alabama at Birmingham Birmingham, AL
10/1/2011	Professor of Medicine (with Tenure)	University of Alabama at Birmingham Birmingham, AL
3/1/2009	Investigator, Nephrology Research and Training Center	University of Alabama at Birmingham Birmingham, AL
10/1/2008	Professor of Surgery	University of Alabama at Birmingham, Birmingham, AL
8/1/2008-3/1/2012	Director of Research	Alabama Transplant Center, Birmingham, AL
8/1/2008	Professor of Medicine	University of Alabama at Birmingham Birmingham, AL
7/2007-7/2008	Professor of Medicine	Uniformed Services University of the Health Sciences, Bethesda, MD
6/2001-6/2007	Associate Professor Medicine	Uniformed Services University of the Health Science, Bethesda, MD
6/2000-8/2007	Medical Director of Transplantation	NIH/NIDDK, Bethesda, MD
6/2000-8/2007	Staff Clinician, Transplantation Branch	NIH/NIDDK, Bethesda, MD
6/1993-6/2000	Staff Physician, Department of Medicine	Durham VA Medical Center, Durham, NC
7/1993-6/2000	Assistant Professor of Medicine	Duke University Medical Center, Durham, NC
6/1991-6/1993	Associate in Medicine	Duke University Medical Center, Durham, NC

AWARDS/HONORS:

5/1979	Alpha Epsilon Delta Honor Society, Johns Hopkins University, Baltimore, MD
5/1980	Phi Beta Kappa, The Johns Hopkins University, Baltimore, MD
5/1985	Alpha Omega Alpha, Duke University Medical Center, Durham, NC
5/1990	Young Investigator Award, American Society of Transplant Physicians

7/1996	Mentored Clinical Scientist Development Award, NIAID, NIH
6/2002	Volunteer Service Award, National Kidney Foundation of the National Capital Area
4/2004	Fellow, American Society of Nephrology
3/2007	Key Opinion Leader, The Transplantation Society
6/2008	Volunteer Service Award, National Kidney Foundation of the National Capital Area
12/2008	Southern Society for Clinical Investigation
02/2009	Senior Scientist, Nephrology Research and Training Center
2009-2019	Best Doctors US and Birmingham, AL
2012-2019	Castle Connolly Top Doctor in Nephrology
2014	UAB Healthcare Leadership Academy Class of 2016
2015-2020	Birmingham's Best Doctors B-Metro Magazine
2017-2020	B-Metro Top Women in Medicine
2017-present	Castle Connolly Exceptional Women in Medicine
2018	5-Star Award, Birmingham VA Medical Center, Birmingham AL

PROFESSIONAL SOCIETIES:

MEMBERSHIPS:

1991	American Society of Nephrology
1994	American Society of Transplantation
2000	International Society of Nephrology
2000	National Kidney Foundation
2006	Transplantation Society
2009	Cystinosis Research Network
2020	Federation of Clinical Immunology Societies

COUNCILS AND COMMITTEES:

American Society of Nephrology

- **Meeting Planning and Organization**

Abstract Reviewer and Session Co-Chairman, ASN, Orlando, FL, 11/1994
Abstract Reviewer and Session Co-Chairman, ASN, San Antonio, TX, 11/1997
Abstract Reviewer and Session Co-Chairman, ASN, Toronto, CN, 10/2000
Section Chair, Transplantation– Basic/Experimental, ASN/ISN World Congress of Nephrology, San Francisco, CA, 11/2001
Section Co-Chair, Program Committee, Transplantation–Outcomes/Epidemiology/Clinical Trials, ASN, Philadelphia, PA, 11/2002
Abstract Reviewer, Transplantation–Outcomes/Epidemiology/Clinical Trials, Renal Week, San Diego, CA, 11/2003
Co-Chair, Program Committee, Transplantation—Immunobiology, Renal Week 11/2008, Philadelphia, PA.
Abstract Reviewer and session moderator, Transplantation—Allograft Dysfunction, ASN Kidney Week 2011, Philadelphia, PA.
Abstract Reviewer, Transplantation—Allograft Dysfunction, ASN Kidney Week 2012, San Diego, CA.
Abstract Reviewer, Basic/Experimental Inflammation, ASN Kidney Week 2013, Atlanta, GA
Abstract Reviewer, Transplantation: Clinical/Translational, ASN Kidney Week 2017, New Orleans, LA.
Abstract Reviewer, Transplantation, Basic/Experimental, ASN Kidney Week 2018, San Diego, CA.
Abstract Reviewer, Transplantation, Basic/Experimental, ASN Kidney Week 2019, Washington, DC.
Abstract Reviewer, Transplantation, Clinical/Translational, ASN Kidney Week 2020, Denver, CO (Virtual due to COVID-19)
Abstract Reviewer, Transplantation, Basic/Experimental, ASN Kidney Week 2021, San Diego, CA.

- **Other Committee Service**

Grants Committee, 11/2003-11/2005; 01/2018-12/2021
Program Committee Renal Week 2006
Post Graduate Education Committee 09/2006-10/2009
Nominating Committee 11/2007-06/2008
Education Committee 06/2008-11/2013
Transplant Advisory Group 11/2009-11/2012

Associate Editor, *Clinical Journal of the American Society of Nephrology*, 07/2013-09/2015
 Associate Editor, *Journal of the American Society of Nephrology*, 10/2017-07/2019
 Team Leader, Transplantation, Renal Weekends/ Highlights 2011-2016
 Faculty, Board Review Course 2016
Public Policy Committee, 01/2018-12/2023
 Member, 1/2018-12/2020

Chair, 01/2021-12/2023

COVID-19 Task Force; Transplantation, March 2020 – February 2021

ASN Kidney Health Initiative

Project Lead, CFAST Kidney Transplant Standards Working Group Fall 2015-2017

Moderator, Transform Transplantation, Capital Market Day for Kidney Health, December 9 2021

American Society of Transplantation—Member, 10/31/1995

- **Key Leadership Positions**

Immediate Past-President, 05/2013-07/2014

President, 06/2012-05/2013

President-Elect, 05/2011-06/2012

Councilor at Large, 5/2007-5/2011

Chair, American Transplant Congress 2012

Co-Chair, American Transplant Congress 2011

Chair Elect, American Transplant Congress 2010

Joint Council, AST/ASTS, 05/2009-07/2014

Co-Chair, Public Policy Committee, 05/2013-06/2017.

Project leader, Transplant Therapeutics Consortium, 05/2013-06/2016

Sensitization in Transplantation Assessment of Risk (STAR) Consensus Conference Sub-Lead Clinical Naïve kidney/liver working group July 2016-present

Advisory Board, Organ and Tissue Preservation Community of Practice, August 2017- June 2019.

- **Meeting Planning and Organization**

Abstract Reviewer and Session Co-Chairman, Annual Meeting, Chicago, IL, 05/1997

Session Co-Chairman, Annual Meeting, Chicago, IL, 05/1998

Abstract Reviewer and Session Co-Chairman, Annual Meeting, Chicago, IL, 05/1999

Abstract Reviewer and Session Co-Chairman, Annual Meeting, Chicago, IL, 05/2000

Abstract Reviewer and Session Co-Chairman, Annual Meeting, Chicago, IL, 05/2001

Abstract Reviewer and Session Co-Chairman, American Transplant Congress, Washington, DC, 05/2002

Co-Chair, Program Committee, Acute/Chronic Rejection, American Transplant Congress, Washington, DC, 05/2003

Co-Chair, Program Committee, Acute/Chronic Rejection, American Transplant Congress, Boston, MA, 05/2004

Co-chair and program organizer, AST Fellows symposium, Dallas, TX, 05/2005.

Co-chair and program organizer, AST Primary Care Symposium, Philadelphia, PA, 05/2005.

Co-chair and program organizer, AST Eastern Regional Meeting, Arlington, VA, 05/2006.

Co-chair and program organizer, AST Fellows symposium, Tempe, AZ, 07/2006.

Co-chair and program organizer, AST Western Regional Meeting, Los Angeles, CA, 07/2006.

Co-Chair, Program Committee, Chronic injury, Basic, American Transplant Congress, San Francisco, CA, 05/2007.

Co-chair and program organizer, AST Winter Symposium, Scottsdale, AZ, 02/2007.

Co-chair and program organizer, AST Fellows symposium, Dallas, TX, 09/2007.

Co-Chair, Program Committee, Chronic Injury, American Transplant Congress, Toronto, Ontario, CA, 05/2008.

Co-chair and program organizer, AST Winter Symposium, Palm Springs, CA, 03/2008.

Organizer and Co-Chair, AST Fellows Symposium 09/2005-09/2007.

Speaker, AST/ASN nephrology core curriculum 05/2007.

Co-chair and meeting organizer, Basic Science Track, AST Fellows Symposium 10/2009, 8/2010, 8/2011, 09/2012.

Meeting Organizer and Curriculum Co-Director, AST Fellows Symposium in Transplant Medicine 09/2013.

Executive Planning Committee: AST's Cutting Edge in Transplantation Meeting, Chandler, AZ, 02/2014.

Co-Chair, Program Committee, Acute Rejection-Basic, World Transplant Congress, San Francisco, CA, 07/2014.

Co-Chair, Program Committee, Preclinical Immunosuppression, World Transplant Congress, San Francisco, CA, 07/2014.

Abstract reviewer, American Transplant Congress, Chicago, IL, 04/2017

Co-Chair, Histocompatibility and Immunogenetics Committee, American Transplant Congress 2018, Seattle, WA.

Co-Chair, Histocompatibility and Immunogenetics Committee, American Transplant Congress 2019, Boston MA.

Abstract reviewer, American Transplant Congress, Philadelphia, PA June 2020.

Abstract Reviewer, American Transplant Congress, Virtual meeting, June 2021.

Abstract Reviewer, American Transplant Congress, Boston, MA, June 2022.

- **Education Committee, 2002-2011**

Co-Chair 05/2004-05/2005

Chair-05/2005-05/2007

Immediate Past chair-05/2007-05/2008

Board Liaison 05/2008-05/2011

- **Other Committee Service**

Member, Tolerance Task Force, 11/1997

Women's Health Community of Practice, 05/2003-2008.

Consensus Conference Committee, 05/2004-05/2005.

AST/NIH Ad hoc Committee, 05/2004-05/2006.

Clinical Trials Committee, 05/2004-05/2007.

Expert Faculty Resource Committee, Co-chair 03/2006-03/2007.

Development Committee, 05/2008-05/2009; 06/2012-05/2013.

Awards and Grants Committee, 03/2007- 2012

Planning Committee, American Transplant Congress 2008-2012

ASN/AST Transplant Fellowship Accreditation Committee Board Liaison 5/2010

Public Policy Committee, Board Liaison 06/2012

Joint Society task force: AJT contract negotiation July 2012-June 2013

World Transplant Congress Scientific Advisory Committee, June 2012-July 2014

FAST committee May 2018 – June 2021

Past president's advisory committee June 2019 – present

Transplant Community Summit Committee June 2019 – April 2021.

Banff Foundation for Allograft Pathology

2022 Board Member

Canadian National Transplant Research Program (a CIHR initiative)

2014- present Member, External Advisory Board

Canadian Institute of Health Research

2017 Member, scientific review panel

July 2017 - present College of Reviewers

The Cochrane Collaboration

01/13/2022- present Member

Cystinosis Research Network

2009-2011 Medical Advisory Committee

2011-present Scientific Review Board

European Society of Transplantation

2018 Ambassador Committee

International Society of Nephrology

Abstract Reviewer, World Congress of Nephrology, Berlin, Germany, 06/2003

Abstract Reviewer, World Congress of Nephrology, Singapore, 06/2005

Kidney Disease Improving Global Outcomes (KDIGO)

2021 Member, Steering Committee, Controversies Conference on Challenges in the Management of the Kidney Allograft: From decline to failure.
Co leader: Immunosuppression Management Work Group

National Kidney Foundation

Nations' Capital Affiliate:

05/2001-05/2003: Professional Advisory Board
06/2003-06/2008: Medical Advisory Board
06/2003-06/2006: Research Committee
06/2004-06/2005: Co-Chair, Public Policy Committee

National:

03/2002-03/2010: Grant Awards Committee
03/2006-03/2008: Co-Chair Grant Awards Committee
03/2008-03/2009: Chair, Grant Awards Committee
03/2021, 03/2022 NephMadness Blue Ribbon Panel Member
03/2021 Scientific Workshop Member: Genetic Testing in Kidney Disease: Transplant
04/2021 Scientific Workshop Member: Understanding Delayed Graft Function

NIH/CSR

10/2021 Ah Hoc Member, Kidney and Urological Systems Function and Dysfunction Study Section
Digestive, Kidney and Urological Systems Integrated Review Group

NIH/NCI

04/2022 Member, Executive Planning Committee
Clinical Trials Planning Meeting (CTPM) on High Risk/Advanced Cutaneous Squamous Cell Cancer (cSCC)

NIH/NIDDK

2011-present Member, Data Safety Monitoring Board NEPTUNE Studies
2013-2016 Chair, DSMB, NEPTUNE 6803, "A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients with Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β 3 Integrin"
June 2015 Invited moderator, APOL1 in Kidney Disease Meeting, College Park, MD
Feb 2018 - present Chair, Ancillary studies committee, APOLLO Trial
Sept 2019 - present Chair, DSMB, THINKER-NEXT Trial
08/2020 – 07/2021 Member, DSMB, NIDDK COVID 19 studies

NIH/NIAID

10/2009-present Steering Committee, **Clinical Trials in Transplantation (CTOT)**
10/2009-09/2015 Mechanistic Studies Steering Committee, **Clinical Trials in Transplantation (CTOT)**
2015 – 2020 Member, review panel, NIH CTOT Ancillary Studies Fund grants

NIH/NCATS

06/2020 National COVID Cohort Collaborative (N3C)
06/2020-01/2022 Co-Chair, Immunosuppression/Immunocompromised Domain
06/2020 Chair, Solid Organ Transplantation subdomain

Pfizer Incorporated

05/2010-05/2011 Advancing Research in Transplantation Awards Review Committee

Roche Research Foundation

2008- 2012 Ad hoc reviewer

Scientific Registry of Transplant Recipients

01/2021-present Co-Chair, SRTR Review Committee

Standardized Outcomes in Nephrology Kidney Transplantation (SONG)-Tx

2016 Member, Transplantation Consensus Group
2017 Member, Expert Working Group, Graft health

Transplantation Society

05/2015 Organizer, Clinical Trials in Organ Transplantation Endpoints Conference
09/2016-present Steering Committee Member, Transplant Therapeutics Consortium
01/2018 Program Organizer, Women in Transplantation and Advancing Therapeutics, Madrid, SP.
01/2019 Program Committee, Transplantation Society 2020, Seoul, Korea
Sub-Committee Co-Chair for the Sex and Gender in Transplantation Track
01/2021 – present Program Committee, Transplantation Society Meeting, Buenos Aires Argentina
Abstract reviewer, TTS 2022 meeting

USRDS

External Advisory Committee, NIDDK

2012-2015 Transplantation Representative

Washington Regional Transplant Consortium (Community)

2002-2004 Member, Medical Advisory Board
2004-2006 Member, Executive Board

Women in Transplantation

5/2009 06/2018 Steering committee, Women's Leadership Network, Women in Transplantation
07/2018 – 09/2020 Co-Chair, Women In Transplantation Leadership Network
09/2020 - Chair, Women in Transplantation Initiative

UNIVERSITY ACTIVITIES:

UAB activities

10/2008-present Member, HSF-GEF Review Committee, University of Alabama Medical Center, Birmingham, AL
10/2009-06/30/11 Co-Chair, Women's Committee, Department of Medicine, University of Alabama Medical Center, Birmingham, AL
3/2010-present Judge, Annual Trainee Research Symposium, Department of Medicine, University of Alabama Medical Center, Birmingham, AL
2010 Member, Endowed Chair Selection Committee: Nephrology
2010-2014 Member, AMC21 Research Strategic Plan Committee- Immunology, Autoimmunity; Transplantation
2011-2014 Member, Department of Medicine Research Development Group
2015 Member, SAC review, Division of Pediatric Nephrology, UAB, Children's of Alabama
2016 Member, Health Leadership Academy, UABHS
2016-2017 Participant, Executive Leadership Orientation Program, UAB
2018 – Jan 2020 Member, executive committee, NIH/NIDDK T32 DK007545-30 postdoctoral training in nephrology

UNMC Activities

Feb 2020 Member, Data Safety Monitoring Board (non-oncology), University of Nebraska Medical Center, Office of the Vice Chancellor for Research
Feb 2020 Member, Internal Medicine Research Committee
Feb 2020 Member, Department of Medicine, Faculty Development Task Force
October 2020 Member, Research and Development Committee, College of Medicine, UNMC
August 2020 Promotion and Tenure Committee, Department of Medicine
Co-chair, January 2021-present
Feb 2021 Member, Gender Equity Community of Practice, Office of Diversity, UNMC
July 2020 Co-Director, Medical Scholars Program

EDITORIAL BOARD MEMBERSHIPS:

06/2007	Guest Editor, <i>Clinical Journal of the American Society of Nephrology</i> Supplement <i>Transplantation</i> 2008.
06/2008-05/2011	Associate Editor, <i>American Journal of Transplantation</i>
10/2010-07/2013	Editorial Board, <i>Clinical Journal of the American Society of Nephrology</i>
05/2011-06/2014	Consulting Associate Editor, <i>American Journal of Transplantation</i>
07/2013-09/2015	Associate Editor, <i>Clinical Journal of the American Society of Nephrology</i>
06/2014-05/31/2019	Associate Editor, <i>American Journal of Transplantation</i>
12/2014-present	Expert Discussant, Centre for Transplantation Evidence, Transplant Library
11/2016-present	Clinical Appraiser, Clinical Practice Guidelines, Centre for Transplantation Evidence
10/01/2017-06/16/2019	Associate Editor, <i>Journal of the American Society of Nephrology</i>
06/01/2019-present	Deputy Editor, <i>American Journal of Transplantation</i>

Ad Hoc Reviewer

American Journal of Kidney Disease
Clinical Journal of the American Society of Nephrology
Clinical Transplantation
Transplantation
Journal of the American Society of Nephrology
Journal of Clinical Investigation
Kidney International
Nature Scientific Reports
New England Journal of Medicine

MAJOR RESEARCH INTERESTS: (2-3 Sentences)

Late kidney allograft failure, the leading cause of late graft loss, is the focus of our research. Through clinical, translational and basic science studies, we are evaluating the etiologies of this disorder in the hopes of identifying biomarkers and potential therapeutic targets in our patient population.

TEACHING EXPERIENCE:

Laboratory Trainees:

7/1999 - 6/2000	Nora Franceschini, MD Nephrology Fellow, Duke University Medical Center Associate Professor of Medicine, University of North Carolina
4/2001 - 11/2003	Xiaojie Zhang, MD, PhD Visiting Fellow, NIDDK Staff scientist, NIDDK
7/2005 - 5/2008:	Raphael Thuillier, PhD Visiting Fellow-NIDDK Investigator, INSERM, U927, Poitiers, France
11/2007 - 7/2008:	Paolo Cravedi, MD, PhD Research Fellow, NIDDK Assistant Professor of Medicine, Mario Negri Research Institute, Milan, IT Assistant Professor of Medicine, Mount Sinai Medical Center, New York, NY
4/2010 - 4/2011	Masatha Thangpong, PhD Research Fellow Division of Nephrology, UAB
6/2011-8/2011	Deirdra Sanders, MSII Meharry Medical College
7/1/2011 - 6/30/2013	Kamal Abdelkader, MD

	ISN Global Outreach Awardee Mansoura Urology and Nephrology Center Mansoura Egypt
07/2015–02/2020	Michael Seifert, MD, MPH Assistant Professor of Medicine Division of Nephrology Children's of Alabama
01/2017–02/2020	Joseph Ladowski, MD PhD Candidate Xenotransplant immunology Surgical Residency, Duke Medical Center
6/1/2017	John Murray, MSI UAB School of Medicine
01/2018-02/2020	Jessie Barra PhD Candidate, Immunology/Microbiology UAB
02/01/2018-06/30/2020	Audrey Ang UAB School of Medicine Koopman Awardee Summer 2018 Resident in Internal Medicine, Medical College of Virginia
10/01/2018	Clemantino Vong De Rosario Undergraduate, UAB Class of 2020
06/12/2019-1/31/2020	Christophe Hansen-Estruch PGY 2, Department of Surgery UAB
05/15/2021	Seth Winfree, PhD Post-doctoral fellow

Clinical Trainees:

8/1/2008 – 12/31/2010	Hasan A. Khamash, MD Assistant Professor of Medicine, UAB
8/1/2008 – 10/15/2010	Mary Prendergast, MD Assistant Professor of Medicine, UAB
7/1/2010 – present	Shikah Mehta, MD Fellow, Division of Nephrology, UAB Assistant Professor of Medicine
6/2011-8/2011	Charles Diskin Jr., MSII UAB School of Medicine
7/01/2012	Dwight M Matthew, PGY 6 Transplant Fellow, UAB
6/2013-8/2013	Charles Diskin Jr., MSIV

UAB School of Medicine
Scholarly Activity

7/1/2012-6/2016	Jayne Locke, MD, MS Assistant Professor of Surgery Division of Transplantation, UAB
7/1/2014-06/30/15	Gaurav Agarwal UAB Transplant Nephrology Fellow Fellow, Transplant Nephrology Assistant Professor of Medicine, UAB
7/2015-6/2016	Frida Rosenblum, MD Assistant Professor of Pathology, UAB Associate Professor of Pathology, UAB
7/1/2015-6/2018	Megan Yanik, MD Nephrology Fellow Children's of Alabama Assistant Professor, Department of Pediatrics, UAB School of Medicine Private Practice, Charlotte, NC
7/1/2015 – 05/2018	John Donnelly Predoctoral Fellow AHRQ NRSA T32 Health Services and Outcomes Research Center for Outcomes and Effectiveness Research and Education (COERE) University of Alabama at Birmingham Assistant Professor, University of Michigan School of Public Health
01/2017 – 12/2018	Nicholas Dietschweiler Undergraduate, Class of 2020 Honors College, UAB
02/2017 – 08/2017	Ellen Eaton, MD Fellow, Division of Infectious Diseases UAB
06/01/2017-12/2019	Miriam Bernard Undergraduate, Class of 2019 Wesleyan College
06/2018-8/2018	Ellen Kasik Undergraduate, Class of 2020 Miami University Ohio
2/2020 03/2021	Doug Franz, MD Assistant Professor of Medicine, Division of Nephrology UNMC
01/2021 – present	Richard Hankins, MD Infectious Disease Fellow Masters Candidate. UNMC
02/2021 – present	Marco Gonzalez-Castellon, MD Assistant Professor, Department of Neurological Sciences Masters Candidate, UNMC

7/2021 – present Prasanth Ravapati, MD
Assistant Professor, Division of Nephrology
UNMC

03/2022 – present Sami Vasitha
Graduate Student
Global Center for Health Security NETEC project manager
UNMC

04/2022 – present Ahmed Nyandemoh
Graduate Student, Biostatistics
UNMC

Great Plains IDeA Clinical and Translational Research (IDeA-CTR) Network

02/2020-present Instructor, CTR903 Multidisciplinary Team Science and Concept Building
Spring 2020, Spring 2021
9/2020 Instructor, CTR901 Introduction to Clinical Research
09/2020 Program Co-Director, Clinical Translational Research Mentored Scholars Program (K12)

Housestaff and Medical Student Education:

8/2008-present Clinic Attending, UAB Transplant Clinic, Birmingham, AL
In this half day clinic, nephrology fellows are supervised in managing recipients post kidney and combined kidney/pancreas transplants.

8/2008-present Clinic Attending, VA Transplant Nephrology Clinic, BVAMC, Birmingham, AL
In this half day clinic, nephrology fellows and supervised in the evaluation and treatment of patients with acute and chronic kidney disease, hypertension and transplantation.

8/2008-present Fellows' Conference Lecture Series, Division of Nephrology
Four lectures are provided each year to nephrology fellows and medicine housestaff rotating on the Nephrology rotations: Transplant immunology 101, Interpreting Allograft Pathology by the Banff Schema, Post-transplant medical management, Summary of the American Society of Nephrology Renal Week Annual Meeting: Transplantation.

8/2010-6/2011 UASOM Introduction to Clinical Medicine (ICM I) Preceptor
In this lecture and practical series, first year UAB medical students learn the elements of history taking. In addition to interviewing patients, interview techniques are reviewed through videos and readings.

02/2015- present UAB Graduate School MIC:741 – Topics in Professional Development
I moderate the presentation on Organ Transplantation. This course is provided as part of the T32 training grant in microbiology and immunology for predoctoral students.

06/2017 – 6/2018 UABMC Core concepts in Nephrology: Late antibody mediated rejection. This is a presentation series on basic science concepts in clinical entities in nephrology.

11/2020 Nephrology Core Curriculum, UNMC Division of Nephrology: Post-transplant complications

11/2021 Nephrology Core Curriculum, UNMC Division of Nephrology: Post-transplant complications

MAJOR LECTURES AND VISITING PROFESSORSHIPS: (selected since 2004)

1. "Depletional Strategies in Kidney Transplantation". George Washington University Division of Nephrology Rounds, April 2004, Washington, DC.
2. "Chronic granulomatous disease: assessment of the medical risks of kidney transplantation". NIDDK Multidisciplinary Grand Rounds, April 2004, Bethesda, MD.
3. "Chronic allograft nephropathy (CAN): Translational approaches to the pathogenesis and treatment". Division of Nephrology, Department of Medicine, University of Kansas, June 2004, Kansas City, MO.
4. "Why do kidney grafts fail? Translational approaches to the pathogenesis and treatment of chronic allograft nephropathy (CAN)". Clinical Center Grand Rounds, National Institutes of Health, November, 2004, Bethesda, MD.
5. "Chronic allograft nephropathy (CAN): Translational approaches to the pathogenesis and treatment". Duke University Medical Center, Division of Nephrology Weekly Conference, December 2004.
6. "BK polyomavirus nephropathy (PVN): What have we learned?" Johns Hopkins Hospital Comprehensive Transplant Center Grand Rounds, Baltimore, MD, March 2006.

7. "BK polyomavirus nephropathy (PVN): What have we learned?" St. Paul's Hospital, University of British Columbia, Citywide Grand Rounds, Vancouver, BC, Canada, April 2006.
8. "BK polyomavirus nephropathy: What have we learned?" University of Alabama at Birmingham Nephrology Research and Training Center Grand Rounds, Birmingham, AL, May 2006.
9. "BK polyomavirus nephropathy: What have we learned?" Northwestern University/Northwestern Memorial Hospital Transplant Series, Chicago, IL, May 2006.
10. "Translational studies in chronic allograft failure". Roscoe R. "Ike" Robinson Memorial Symposium, Duke University Medical Center, Durham NC, October 2006.
11. "Translational approaches to chronic graft injury". Albert Einstein College of Medicine/Montefiore Hospital Division of Nephrology Grand Rounds, Bronx, NY, January 2007.
12. "Translational approaches to chronic graft injury". Mount Sinai School of Medicine, Division of Nephrology Research Conference, New York, NY, January 2007.
13. "Novel approaches to the management of post-transplant diabetes mellitus". UCSF Kidney Transplant Symposium, Napa Valley, CA, May 2007.
14. "What's New in Transplant Allograft Loss". Yale University School of Medicine, Division of Nephrology, Nephrology Rounds, New Haven, CT, November 2007.
15. "Can Transplants Last Forever? Strategies to prevent graft fibrosis". University of Toronto Multi-Organ Transplant Round, Toronto, Ontario, CA, November 2007.
16. "Can Transplants Last Forever? Strategies to prevent graft fibrosis". University of Western Ontario Multi-Organ Transplant Rounds, London, Ontario, CA, November 2007.
17. "Translational studies in chronic allograft injury". Georgetown University, Department of Medicine, Division of Nephrology Grand Rounds, Washington, DC, January 2008.
18. "Translational approaches to understanding chronic graft injury". Renal Grand Rounds, Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA, April 2008.
19. "Translational approaches to understanding chronic graft injury". Transplantation Grand Rounds, University of Alberta, Edmonton, Edmonton, Alberta, CA, May 2008.
20. "Allograft fibrosis: Understanding why kidney grafts fail". The Rachel McKenna Memorial Lecture, University of Calgary, Calgary, Alberta, CA, December 2008.
21. Transplantation 2008: The clinical year in review. Citywide Nephrology Grand Rounds, University of Calgary, Calgary, Alberta, CA, December 2008.
22. "Why do kidney allografts fail? Translational approaches to the pathogenesis and treatment of chronic graft injury. Nephrology Research and Training Center Conference, University of Alabama at Birmingham, Birmingham, AL, March 2008.
23. "Why do kidney allografts fail? Translational approaches to the pathogenesis and treatment of chronic graft injury". Northwest Kidney Centers, Nephrology Grand Rounds, Seattle, WA, March 2009.
24. "Innate and Adaptive Immune Responses in Long-Term Kidney Allograft Failure". Emory University, Division of Transplantation, Department of Surgery, Transplant Conference, Atlanta, GA, April 2009.
25. "Allograft Fibrosis: Innate and adaptive immune mechanisms". BC Provincial Transplant Day 2009, Vancouver, British Columbia, CA, June 2009.
26. "Late kidney allograft failure" and "Immune monitoring after kidney transplantation". XV Paulista Congress of Nephrology, Campos Do Jordao, Sao Paulo, Brazil, September 2009.
27. "Allograft Fibrosis: Innate and Adaptive Mechanisms of Chronic Kidney Injury". Ruth Abramson Visiting Professor, Mount Sinai School of Medicine, Division of Nephrology, New York, NY, June 2010.
28. "Innate and adaptive immune mechanisms of chronic allograft injury". Medicine Grand Rounds, University of Alabama at Birmingham, Birmingham, AL. August 2010.
29. "Current Advances in Clinical Immunosuppression". Plenary Symposium Innovations in Immunosuppression, XXIII International Congress of the Transplantation Society, Vancouver, British Columbia, Canada, August 2010.
30. "Stopping the Horse Out of the Barn—Can We Impact Late Pathways?". 2011 Annual Meeting of the Canadian Society of Transplantation. Mont-Tremblant, Quebec, CA, March 2011.
31. "Why do kidney allografts fail?" Visiting professor, Division of Nephrology, University of Chicago, Chicago, IL, March 2011.
32. Why Do Kidney Allografts Fail? Translational Approaches to the Pathogenesis and Treatment of Kidney Transplant Failure". Visiting professor, Division of Nephrology, University of Colorado, Denver, CO, February 2012.
33. "Non-Adherence to Immunosuppressant Medications: Scope and Therapeutic Strategies". Invited Speaker, Canadian Society of Transplantation Annual Meeting February 2012, Quebec City, Quebec, CA.
34. "Why Do Kidney Allografts Fail? Translational Approaches to the Pathogenesis and Treatment of Kidney Transplant Failure". Visiting Professor, University of Montreal Multi-Organ Transplant Program, Montreal, Quebec, Canada, March 2012.

35. "Why Do Kidney Allografts Fail? Translational Approaches to the Pathogenesis and Treatment of Kidney Transplant Failure". Transplant Grand Rounds, Mayo Clinic, Rochester, MN, March 2013.
36. "Kidney Transplantation: Reflections on the Past and Present and Speculation for the Future". Nephrology Grand Rounds, Indiana University School of Medicine, Indianapolis, IN, April 2013.
37. "Kidney Transplantation: Reflections on the Past and Present and Speculation for the Future". Nephrology Grand Rounds, Henry Ford Hospital, Detroit, MI, July 2013.
38. "The Barriers of Successful Kidney Transplantations: Translational Studies to Improve Outcomes". Dr. Leslie & Grazia Dornfeld and Lynda & Stewart Resnick Endowment's 5th Annual Great Teachers in Medicine Lecture and 3rd Annual Medial Scholarship Recipient George Washington University School of Medicine, Washington DC, April 2014.
39. "Late Allograft Failure: Translational Studies to Improve Outcomes." Nephrology Grand Rounds, University of California at San Francisco, San Francisco, CA, April 2014.
40. "The Success Story of Kidney Transplantation and Challenges for the 21st Century". Medicine Grand Rounds, The Ohio State University, Columbus, OH, May 2014.
41. "Late Allograft Failure: Translational Studies to Improve Outcomes." The Charlie Orosz Memorial Lecture, Comprehensive Transplant Institute, The Ohio State University, Columbus, OH, May 2014.
42. "The Challenges of Kidney Transplantation in the 21st Century". Medical Grand Rounds, University of Utah School of Medicine, Salt Lake City, UT, Sept 2015.
43. "Late Allograft Failure: A continuing challenge in kidney transplantation". Special Seminar, New York University Hospital, New York, NY, April 2016.
44. "Late Kidney Allograft Failure: Antibody and Cellular Mechanisms". Nephrology Grant Rounds, Vanderbilt University, Nashville, TN, September 2017.
45. "Late Kidney Allograft Failure: Translational Studies to Improve Outcomes". Multidisciplinary Organ Transplant Symposium. University of Western Ontario, London, Ontario, CA. October 2018.
46. "The Challenges of Kidney Transplantation in the 21st Century". Medicine Grand Rounds, Victoria Hospital, London, Ontario, CA. October 2018.
47. "The Unmet Therapeutic Needs in Kidney Transplantation: The Process and Results of a Call to Action". Nephrology Grand Rounds, Westmead Institute for Medical Research, University of Sydney at Westmead Hospital, Sydney, NSW, Australia, July 2019.
48. "Unmet Therapeutic Needs: What Are They and Can We Find the Fixes?" Larry Chan Visiting Professor, University of Colorado. Aurora, CO. December 2019.
49. "Navigating Success as a Woman in Academic Medicine: A Perspective." Drs. Coy D and Rachel F Fitch Endowed Lecture in Medical Leadership. Medical Grant Rounds, St. Louis University, St. Louis, MO. March 2021 (Virtual).
50. "Unmet Therapeutic Needs in Kidney Transplantation: Finding Solutions to Long-Standing Barriers". Visiting Professor, Division of Nephrology, University of Chicago, June 2021 (virtual).
51. "Navigating Success as a Woman in Academic Medicine: A Perspective." 15th Annual Nancy E. Gary Lecture. Women in Nephrology Annual Meeting at the American Society of Nephrology Kidney Week (virtual), November 6, 2021.

PATENTS

Urine Biomarkers for Detecting Graft Rejection

US Patent Application 16/110,964 filed 23-Aug-2018

Issued 22 February 2021

Submitted by Cleveland Clinic on behalf of Roslyn B Mannon and Robert Fairchild

Ref 2016-257-03

Licensed to Eurofins

Bayesian Clinical Decision Model for Determining the Probability of Transplant Glomerulopathy

US Patent Application 13/083,184 filed 08-April-2011

Patent number 8,510,245,B2, issued 30-Aug-2013

Submitted by the US Army on behalf of Alexander Stojadinovic, Eric A. Elster, Doug K. Tadaki, John S. Eberhardt, III, Trevor Brown, Thomas A. Davis, Jonathan Forsberg, Jason Hawksworth, Roslyn Mannon

GRANT SUPPORT: (PAST AND CURRENT)

ACTIVE

1U01DK115997 (PI: Mannon as of 6/1/2019) **09/25/2017 – 05/31/2022** **0.36 calendar**
NIH/NIDDK **\$277,820**
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Centers
 Role: Co-Primary Investigator, UNMC
 The intent of this application is to enroll recipients of African American deceased and living donor kidneys and African American Living donors and obtain their clinical information and DNA to better understand the impact of APOL1 double mutations.

RFA AI-20-029 (PI: Heeger) **08/01/2022 – 07/31/2029** **1.2 calendar**
NIH/NIAID **\$879,409**
 Clinical Trials in Organ Transplantation
Biomarker guided CNI-Substitution in Kidney Transplantation
 Role: Site Primary Investigator and Senior Investigator
 This is a multi-center clinical trial involving novel biologic and cellular therapies to mitigate renal allograft inflammation and prolong allograft function using a trial strategy guided by biomarkers.

Great Plains IDeA-CTR Data Science Pilot Funding **07/01/2022 – 06/30/2023**
Artificial Intelligence/Machine Learning Pilot Project
Using deep-learning to identify imaging signatures of renal allograft rejection
 This application is pilot funding to develop the spatial transcriptomics platform at UNMC initiated on kidney transplant T cell mediated rejection from human biopsies.

PENDING

VA Merit Review Award (PI: Mannon) **10/01/2022 – 09/30/2026**
Department of Veterans Affairs **\$660,000**
The Role of HMGB1 in the Inflammatory Response of Calcineurin Inhibitor Nephrotoxicity
 The objective of this application is to study the autocrine and paracrine impacts of HMGB1 release in CNI-nephrotoxicity.

COMPLETED

5K08AI001389-02 (PI: Mannon) **04/01/1996-06/18/2000** **9 calendar**
NIH/NIAID
Regulation of Thymocyte Apoptosis by Thromboxane A2
 The goal of this project was to assess the mechanisms of TXA2 in thymic development and impact on T cell immunology.

1Z01DK062008 (PI: Mannon) **10/1/2006-07/30/2008** **6 calendar**
NIH/NIDDK **\$1,255,167***
Chronic Allograft Nephropathy (CAN): Translational Approaches to the Pathogenesis

1Z01DK062008 (PI: Mannon) **10/01/2003-09/30/2006** **12 calendar**
NIH/NIDDK
The Role of Connective Tissue Growth Factor in Chronic Allograft Nephropathy

1Z01DK062005-08 (PI: Mannon) **10/01/2007-09/30/2008** **6 calendar**
NIH/NIDDK **\$459,058**
Kidney/Pancreas Allograft Rejection: Clinical Studies and Technology Development
 The goal of this project was to identify biomarkers of allograft injury.

5U01 AI058013 (PI: Matas) **02/15/2005 – 01/31/2010** **0.36 calendar**
NIH/NIAID **\$157,609**
Long-term deterioration of kidney allograft function
 Role: Co-Investigator, UAB
 The major goal of this project is to create a transplant database with information from multiple transplant centers for the purpose of conducting research to help improve transplant outcomes and the care of the transplant.

5U19 A1070119 (PI: Matas) NIH/NIAID Genomics of kidney transplantation Role: Principle Investigator, UAB The objective of this study is to evaluate genetic factors that may predict the long-term function of transplanted kidneys.	07/01/2006 – 06/30/2011	1.2 calendar
R43A1081372-01 (PI: Brasile) NIH/NIDDK Potential to immunocloak renal allografts Role: Collaborator This project will investigate a non-systemic treatment applied to the kidney allograft to “immunocloak” the interface between the kidney graft tissue and host immune response using a bioengineered physical barrier.	07/01/2009 – 06/30/2011	1.2 calendar
3U01A1063594-0751 (PI: Heeger) NIH/NIAID Individualizing Therapy for Kidney and Heart Transplant Recipients Role: PI This is a collaborative project amongst the PI’s of the Clinical Trials in Transplantation with the goal of standardizing laboratory methods and cross validating techniques and biomarkers in acute and chronic allograft injury.	09/13/2010-09/12/2011	N/A
RO1 DK75532 (PI: Agarwal) NIH/NIDDK Cytokine modulation of heme oxygenase-1 in chronic kidney transplant rejection Role: Co-Investigator The major goals of this project are to examine the role of heme oxygenase-1 in mediating the protective effects of interleukin-10 in chronic kidney transplant rejection.	08/01/2006 – 05/31/2011	0.6 calendar
ITN524ST-CTOT-12 (PI: Newell) NIH/NIAID The Collaborative Network for Clinical Research in Immune Tolerance Role: Principle Investigator, UAB The major goal of this project is to assess the frequency of a previously defined tolerance signature in a broad population of renal transplant recipients.	06/01/2010 – 04/30/2014	0 calendar
5R21NR013660 (Gordon) NIH/NINR Optimizing kidney transplant patients informed consent for increased risk donors Role: Principal Investigator, UAB The objective of this study is to Develop a web-based tool that educates and assesses kidney transplant candidates’ comprehension of increased risk donor kidneys. We will then compare the effectiveness of the current informed consent processes supplemented by this tool with the current consent processes alone for kidney transplant candidates.	07/04/2012-06/30/2014	1.2 calendar
1R01DK083390-01 (PI: George) NIH/NIDDK The Role of Heme Oxygenase-1 in the Immune Response Role: Co-Investigator The goal of this project is to define how HO-1 affects chronic vascular injury in kidney allografts and the role of dendritic cell function.	07/01/2011 – 06/30/2016	0.6 calendar
1U01A1084150 (PI: Newell) Clinical Trials in Organ Transplantation Preserving renal function & protective immunity via anti-LFA1-based CNI avoidance Role: Principal Investigator and Senior Investigator, UAB This project is a multi-center clinical trial involving multiple solid organs utilizing a novel immunosuppressive strategy without calcineurin inhibitors, which will evaluate safety and efficacy of these regimens as well as investigate the mechanisms of native and kidney graft injury and viral pathogenesis.	09/25/2009 – 08/31/2016 \$567,594	6 calendar

5U19 A1070119 (PI: Matas) **07/01/2006 – 07/31/2016** **1.2 calendar**
NIH/NIAID **\$109,952**
Genomics of kidney transplantation
 Role: Principal Investigator, UAB
 The objective of this study is to evaluate genetic factors that may predict the long-term function of transplanted kidneys.

HHSN272201100036C (PI: Gnnann) **09/28/2011 – 09/27/2016** **0.6 calendar**
NIH/NIAID **\$38,125**
The safety, tolerability and pharmacokinetic properties of CMX001 in renal transplant recipients with BKV viremia: a phase IIA randomized, double-blind, placebo controlled, dose-escalation study.
 Role: Co-Investigator
 The goal of this study is to determine the safety, tolerability and optimal dose of CMX001 in kidney or kidney/pancreas transplant patients with BKV viremia using a dose-escalation study design.

5U01AI118594 (PI: Stock) **07/01/2015 – 06/30/2020** **0.36 calendar**
NIH/NIAID **\$130,060**
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients.
 Role: Site Principal Investigator, UAB
 The goal of this application is to investigate the use of CCR5 blockade (maraviroc) as a strategy to improve kidney function following transplantation in the HIV positive recipient.

5U01AI063594 (PI: Heeger) **09/01/2015 – 08/31/2017** **1.2 calendar**
NIH/NIAID **\$212,055**
Effects of Inhibiting Early Inflammation in Kidney Transplant Patients – Equipment
 Role: Site Principal Investigator, UAB
 The goal of this study is to evaluate whether taking infliximab just prior to transplant surgery along with usual transplant medicines will protect the donated kidney from damage caused by TNF-alpha and help keep the transplanted kidney healthy for a longer period of time.

P01CA210946-01A1 (PI: Elmets) **09/01/2017 – 06/30/2020** **0.6 calendar**
NIH/DHHS **\$470,723**
RXR Reginoids for Cancer Chemoprevention
 Role: Co-Investigator for project 1
 The goal of this application is to evaluate the safety and efficacy of unique agents for the treatment of skin cancer.

P30-DK079337 (PI: Agarwal) **09/01/2008 - 07/31/2023** **0.6 calendar**
NIH/NIDDK **\$1,180,419**
UAB-UCSD O'Brien Center for Acute Kidney Injury Research
Core A co-director

The goal of this application is to provide shared core facilities to enhance collaborations and further research in kidney-related research, foster interactions among investigators from different backgrounds and disciplines whose shared interest is in kidney research, and provide intellectual resources and infrastructure to attract new and established investigators to AKI research

1R43DK121626 - 01A1 (PI: Young L) **7/1/2019-6/30/2021** **0.36 Cal months**
NIH/NIDDK **\$116,431**
YT-001 treatment to mitigate acute kidney injury
 Role: Co-investigator, UAB

This SBIR collaboration is to perform pre-clinical studies using a rat model of acute kidney injury and test a novel therapy.

5U01AI063594-16 (PI: Heeger) **02/01/2020 – 08/31/2020**
NIH/NIAID **\$19,915**
Effects of inhibiting early inflammation in kidney transplant patients - Cell Death Pathways and Heart Transplant Rejection

Role: PI

This is a collaborative project amongst the PI's of the Clinical Trials in Transplantation with the goal of validating urine gene expression signatures using a nanostring platform from urine mRNA focusing on distinguishing inflammatory conditions.

1U01AI113362 (PI: Vincenti)
NIH/NIAID

07/01/2014 – 06/30/2021
\$205,522

1.2 calendar

Clinical Trials in Organ Transplantation

Novel Therapies to Modulate the Inflammatory Response in Renal Allografts

Role: Site Primary Investigator and Senior Investigator

This is a multi-center clinical trial involving novel biologic and cellular therapies to mitigate renal allograft inflammation and prolong allograft function.

In addition to the grants listed above, Dr. Roslyn Mannon is involved in clinical trials. The cyclic and unpredictable nature of the activities in these trials makes it impossible to assign a precise percent effort for each trial. Dr. Mannon has reviewed her clinical study obligations and confirms that the aggregate effort on all trials listed below does not exceed 1% of institutional effort.

VA Merit Review Award (PI: Mannon)
Department of Veterans Affairs

10/01/2016 – 03/30/2022
\$650,000 (no cost extension)

AMP Kinase Activation in Calcineurin Inhibitor Nephrotoxicity

This application will explore the role of AMP activated kinase in mitigating the nephrotoxicity associated with a calcineurin inhibitor cyclosporine A using a complementary approach of in vitro and in vivo mouse models

2U01AI113362-08 (PI: Vincenti)
NIH/NIAID

08/05/2021 - 03/31/2022
\$176,206

1.2 calendar

Clinical Trials in Organ Transplantation

Applying precision MEdicine to optimize desensitization with novel bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)

Role: Site Primary Investigator and Senior Investigator

This is a multi-center clinical trial involving novel biologic and cellular therapies to mitigate renal allograft inflammation and prolong allograft function in sensitized and non sensitized kidney transplant recipients.

Amgen 073

09/2008-09/2012

0.12 calendar

Role: UAB PI

The goal of this study is to assess the impact of renal transplantation on bone health and remodeling following kidney transplantation.

Quark Pharmaceuticals, Inc. (PI: Goodman)

04/28/2009 – 04/27/2014
\$112,421

0.12 calendar

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK and Clinical Activity of 15NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation (QRK.006)

Role: Sub-Investigator

The major goal of this study is two in 2 parts: part A will be randomized, dose escalation study to determine the maximum tolerated dose followed by an optional open-label cohort. Part B will evaluate in a double blind manner, the safety, and clinical activity of 15NP.

Astellas Pharma Global Development, Inc. (PI: Mannon)

06/07/2013 – 06/06/2018
\$139,851 (project total)

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients (7163-CL-0108)

Role: Principal Investigator, UAB

The goal of this study is to determine how the study drug works to prevent rejection of a transplanted kidney when used in combination with other anti-rejection medicines that are routinely used for kidney transplantation.

Alexion Pharmaceuticals, Inc. (PI: Mannon)

06/25/2013 – 06/24/2018
\$31,064 (project total)

A Randomized, Open-Label, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Living Donor Kidney Transplant Recipients Requiring Desensitization Therapy (C10-001)

Role: Principal Investigator, UAB

The goal of this study is to determine if the study drug is safe and could be used following desensitization therapy to prevent a condition called antibody mediated rejection (AMR).

Alexion Pharmaceuticals, Inc. (PI: Mannon)

10/31/2014 – 10/30/2019

\$169,803 (project total)

A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multi-Center Study of Eculizumab for the Prevention of Delayed Graft Function after Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function (ECU-DGF-201)

Role: Principal Investigator, UAB

The goal of this study is to determine if the study drug is safe and could be used to prevent delayed graft function following kidney transplantation.

Quark Pharmaceuticals, Inc. (PI: Mannon)

12/08/2015 – 12/07/2020

\$79,302 (project total)

A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Study Drug for Prevention of Delayed Graft Function in Recipients of a Donation after Brain Death Older Donor Kidney Transplant.

Role: Principal Investigator, UAB

The goal of this study is to test whether or not the study drug is effective in preventing or reducing the severity of DGF. Another purpose is to test the safety of the study drug.

Mallinckrodt Inc. (PI: Mannon)

05/01/2016-04/30/2019

\$586,798

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant with Acthar

Role: Co-Investigator and Site PI

The goal of this study is to determine if treatment with Acthar is safe and effective for patients with chronic antibody mediated rejection to mitigate graft failure mediated by donor alloantibody.

Transplant Genomics (PI: Mannon)

04/17/2017 – 04/16/2019

\$7,700

Molecular Biomarkers in Renal Transplantation

Role: Principal Investigator, UAB

The goal of this study is to see if blood can be used to predict and diagnose certain conditions of a transplanted kidney.

BIBLIOGRAPHY:

MANUSCRIPTS:

(Numbered, in chronological order)

Manuscripts already published

1. Bozzaro S, **Bernstein R**, Roseman S. A plasma membrane factor inhibiting intracellular adhesion in *Polysphondylium pallidum*. *Cell Differentiation* 1983;12:109-112.
2. Cohen HJ, **Bernstein RJ**, Grufferman S. Role of immune stimulation in the etiology of multiple myeloma: a case-control study. *Am J Hematology* 1987; 24:114-126.
3. Navetta FI, Barber MJ, Gurbel PA, Moreadith RW, **Bernstein R**, Hlatky MA, Coleman RA, Bashore TM. Myocardial ischemia in constrictive pericarditis. *Am Heart J* 1988;116(4):1107-1111.
4. Spurney RF, **Bernstein RJ**, Ruiz P, Pisetsky DS, Coffman TM. Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. *Prostaglandins* 1991; 42:15-28.
5. Thel MC, **Mannon RB**, Allen NB. Hyperrenin-hyperaldosterone-dependent malignant hypertension in polyarteritis nodosa. *Southern Medical Journal* 1993; 86:1400-1402.
6. **Mannon RB**, Sundar KS, Sanfilippo F, Coffman TM. Alterations in renal interleukin-1 production during kidney transplant rejection in the rat: Effects of high dose methylprednisolone. *Transplantation* 1993; 56(5):1157-1162.
7. Raymond JR, Arthur JM, **Mannon RB**. Management of hypertensive emergencies and urgencies. *North Carolina Medical Journal* 1994; 55(7):295-303.
8. **Mannon RB**, Nataraj C, Kotzin BL, Griffiths R, Geier S, Ibrahim S, Sanfilippo FP, Platt JL, Kurlander R, Coffman TM. Rejection of kidney allografts by MHC class I deficient mice. *Transplantation* 1995; 59(5):746-755.
9. **Mannon RB**, Kotzin BL, Roper E, Nataraj C, Kurlander R, Coffman TM. The intragraft CD8⁺ T cell response in renal allograft rejection in the mouse. *Transplantation* 1996; 62(1):96-104.
10. **Mannon RB**, Coffman TM, Mannon PJ. Distribution of binding sites for thromboxane A₂ in the mouse kidney. *Am J Physiol* 1996; 271(40):F1131-8.
11. **Mannon RB**, Kotzin BL, Nataraj C, Ferri K, Roper E, Kurlander RJ, Coffman TM. Downregulation of T cell receptor expression by CD8⁺ lymphocytes in kidney allografts. *J Clin Invest* 1998; 101(11):2517-2527.
12. Coffman TM, Spurney RF, **Mannon RB**, Levenson R. Thromboxane A₂ modulates the fibrinolytic system in glomerular mesangial cells. *Am J Physiol* 1998; 275(44):F262-9.
13. Neuringer IP, **Mannon RB**, Coffman TM, Parsons M, Burns K, Yankaskas JR, Aris R. Immune cells in a mouse airway model of obliterative bronchiolitis. *Am J Respiratory Cell Mol Biol* 1998, 19:379-386.
14. Thomas D, **Mannon RB**, Mannon PJ, Latour, A, Smithies O, Koller, B H, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A₂. *J Clin Invest* 1998, 102:1994-2001.
15. **Mannon RB**, Kopp JB, Ruiz P, Griffiths R, Bustos M, Platt JL, Klotman PE, Coffman TM. Chronic rejection of mouse kidney allografts. *Kidney Int* 1999, 55:1935-1944.
16. Mannon PJ, Kanungo A, **Mannon RB**, Ludwig KA. Peptide YY/Neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon. *Regulatory Peptides* 1999, 83:11-19.
17. **Mannon RB**, Roberts K, Ruiz P, Laubach V, Coffman TM. Inducible nitric oxide synthase is not required for efficient rejection of cardiac allografts. *Journal of Heart and Lung Transplantation* 1999, 18(9): 819-827.
18. Nataraj CN, Oliverio MO, **Mannon RB**, Mannon PJ, Auduoly L, Smithies OS, Coffman TM. Angiotensin II regulates immune responses through a calcineurin-dependent pathway. *Journal of Clinical Investigation* 1999, 104(12): 1693-1701.
19. **Mannon RB**, Doyle C, Griffiths R, Bustos M, Platt JL, Coffman TM. Altered intragraft immune responses and improved renal function in MHC class II deficient mouse kidney allografts. *Transplantation* 2000, 69(10): 2137-2143.
20. Neuringer IP, Walsh SP, **Mannon RB**, Parsons M, Gabriel S, Aris RM. Enhanced cytokine gene expression in mouse airway obliterative bronchiolitis. *Transplantation* 2000, 69(3): 399-405.
21. **Mannon RB**, Nataraj C, Pisetsky DS. Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides. *Cellular Immunology* 2000, 201(1): 14-21.
22. Goulet JL, Griffiths RC, Ruiz P, **Mannon RB**, Flannery P, Platt JP, Koller BH, Coffman TM. Deficiency in 5-lipoxygenase accelerates renal allograft rejection in mice. *Journal of Immunology* 2001, 167:6631-6636.
23. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, **Mannon R**, Koller BH, Coffman TM. Receptors for prostaglandin E₂ that regulate cellular immune responses in the mouse. *Journal of Clinical Investigation* 2001, 108:1229-1235.
24. **Mannon RB**, Griffiths R, Ruiz P, Platt JL, Coffman TM. Absence of donor MHC antigen expression ameliorates chronic kidney allograft rejection. *Kidney International* 2002, 62(1):290-300.
25. Hoffman SC, Kampen RL, Amur S, Sharaf MA, Kleiner DE, Hunter K, Swanson SJ, Hale DA, **Mannon RB**, Blair PJ, Kirk AD. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia/reperfusion injury. *Transplantation* 2002, 74(7):916-923.
26. Swanson SJ, Hale DA, **Mannon RB**, Kleiner DE, Cendales LC, Chamberlain CE, Polly SM, Harlan DM, Kirk AD.

- Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. *The Lancet* 2002, 360: 1662-1664.
27. Li R-M, **Mannon RB**, Kleiner D, Tsokos M, Filie A, Kirk AD, Kopp JB. BK and SV 40 viruses associated with polyoma virus nephropathy occurring in renal transplant recipients. *Transplantation* 2002, 74(11):1497-1504.
 28. Franseschini N, Cheng O, Zhang X, Ruiz P, **Mannon RB**. Prolyl-hydroxylase inhibition ameliorates chronic allograft nephropathy in the mouse. *American Journal of Transplantation* 2003, 3(4):396-402.
 29. Cendales LC, Swanson SJ, Kirk AD, **Mannon RB**, Hale DA. Delayed auto-transplantation of a solitary kidney facilitated by pump perfusion preservation. *Surgery* 2003, 133(4):438-439.
 30. Kirk AD, Hale DA, **Mannon RB**, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). *Transplantation* 2003, 76(1):120-129.
 31. McNally M, **Mannon RB**, Javor ED, Swanson SJ, Hale DA, Gorden P, Kirk AD. Successful renal transplantation in a patient with congenital generalized lipodystrophy. A case report. *American Journal of Transplantation* 2003, 4:447-449.
 32. Hoffmann S, Park J, Jacobson LM, Muehrer RJ, Lorentzen D, Kleiner D, Becker YT, Hullett DA, **Mannon R**, Kirk AD, Becker BN. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. *Kidney International* 2004, 66:1686-1693.
 33. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, **Mannon RB**, Roederer M, Kirk AD. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. *American Journal of Transplantation* 2005; 5:465-474.
 34. Hoffmann SC, Hale DA, Kleiner DE, **Mannon RB**, Kampen RL, Jacobson LM, Cendales LC, Swanson SJ, Becker BN, Kirk AD. Functionally significant renal allograft rejection is defined by transcriptional criteria. *American Journal of Transplantation* 2005; 5: 573-581.
 35. Elster EA, Hale DA, **Mannon RB**, Cendales LC, Kleiner D, Swanson SJ, Kirk AD. The Surgical Transplant Physical Exam: Correlation Of Renal Resistance Index And Biopsy Proven Chronic Allograft Nephropathy. *Journal of the American College of Surgeons* 2005; 200(4): 552-556.
 36. Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman CB, Leonard MB, **Mannon RB**, Sarwal M, Schneider JA, Skovy F, Sonies BC, Thoene JG, Trauner DA, Gahl WA. First NIH/Office of Rare Diseases Conference on cystinosis: Past, present, and future. *Pediatric Nephrology* 2005, 20(4): 452-4.
 37. Zhang Y, Choyke PL, Lu H, Takahashi H, **Mannon RB**, Zhang X, Marcos H, Li KCP, Kopp JB. Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325. *Journal of the American Society of Nephrology* 2005, 16(6): 1752-1757.
 38. Chamberlain C, FitzGibbons E, Wasserman EM, Butman J, Kettl D, Hale, D, Kirk AD, **Mannon RB**. Idiopathic intracranial hypertension following kidney transplantation: A case report and review of the literature. *Pediatric Transplantation* 2005, 9:545-550.
 39. Kirk AD, **Mannon RB**, Kleiner DE, Swanson SJ, Kampen RL, Cendales LK, Elster EA, Wakefield T, Chamberlain C, Hoffman SC, Hale DA. Results from a human renal allograft tolerance trial evaluating T cell depletion with Alemtuzumab combined with Deoxyspergualin. *Transplantation* 2005,80(8): 1051-1059.
 40. **Mannon RB**, Hoffmann SC, Kampen RL, Cheng OC, Kleiner DE, Ryschkewitsch C, Curfman B, Major E, Hale DA, Kirk AD. Molecular evaluation of BK polyomavirus nephropathy. *American Journal of Transplantation*, 2005, 5: 2883-2993.
 41. Kirk AD, Hale DA, Ford E, Kleiner DE, Kampen RL, Elster EA, Swanson SJ, Cendales LC, Cropper T, Hale L, Jordan S, Koussis T, Peretti J, Sloane A, Salaita C, Ring M, Chamberlain C, **Mannon RB**. Solid organ transplantation at the National Institutes of Health: development of a research-based transplantation practice. *Clinical Transplantation* 2005: 131-44.
 42. Bolanowski A, **Mannon RB**, Holland SM, Malech HL, Aschan J, Palmblad J, Hale, DA, Kirk AD. Successful renal transplantation in patients with chronic granulomatous disease. *American Journal of Transplantation* 2006, 6:636-639.
 43. Xu H, Zhang X, **Mannon RB**, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell bound CD154. *Journal of Clinical Investigation* 2006, 116:769-774.
 44. Kirk AD, Hale DA, **Mannon RB**, Swanson SJ. Autoimmune thyroid disease after renal transplantation using depletion induction with Alemtuzumab. *American Journal of Transplantation* 2006, 6:1084-1085.
 45. Kowalski RJ, Post DR, **Mannon RB**, Sebastian A, Wright HI, Sigle G, Burdick J, Elmagd KA, Zeevi A, Lopez-Cepero M, Daller JA, Gritsch HA, Reed E, Jonnson J, Hawkins D, Britz JA. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. *Transplantation* 2006; 82: 663-668.
 46. Cheng O, Thuillier R, Sampson E, Schultz G, Ruiz P, Zhang X, Yuen PST, **Mannon RB**. Connective tissue growth factor (CTGF) is a biomarker and mediator of kidney allograft fibrosis. *American Journal of Transplantation*, 2006,

47. Kowalski RJ, Zeevi A, **Mannon RB**, Britz JA, Carruth LM. Immunodiagnostics: evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. *Journal of Immunotoxicology* 2007; 4:225-232.
48. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, **Mannon RB**, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickleleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madruga L, Salomon DR, Seron D, Sheaff M, Weening JJ. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). *American Journal of Transplantation* 2007; 7: 518-526.
49. Girlanda R, Kleiner DE, Duan Z, Ford EAD, Wright EC, **Mannon RB**, Kirk AD. Monocyte infiltration and kidney allograft dysfunction during acute rejection. *American Journal of Transplantation*, 2008; 8:600-607.
50. Elster EA, Leiser DB, Morissette C, Pepek JM, Quiko A, Hale DA, Chamberlain C, Salaita C, Kirk AD, **Mannon RB**. Obesity Following Kidney Transplantation and Steroid Avoidance Immunosuppression. *Clinical Transplantation* 2008; 22:354-359.
51. K. Solez, R. B. Colvin, L. C. Racusen, M. Haas, B. Sis, M. Mengel, P. F. Halloran, W. Baldwin, G. Banfi, A. B. Collins, F. Cosio, D. S. R. David, C. Drachenberg, G. Einecke, A. B. Fogo, I. W. Gibson, D. Glotz, S. S. Iskandar, E. Kraus, E. Lerut, **R.B. Mannon**, M. Mihatsch, B. J. Nankivell, V. Nickleleit, J. C. Papadimitriou, P. Randhawa, H. Regele, K. Renaudin, I. Roberts, D. Seron, R. N. Smith and M. Valente. Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions. *American Journal of Transplantation* 2008; 8:753-760.
52. CE Chamberlain, S Penzak, RM Alfaro, R Wesley, CE Daniels, D Hale, and AD Kirk, and **RB Mannon**. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. *American Journal of Transplantation* 2008; 8:1297-1302.
53. Thullier R, Cheng O, **Mannon, RB**. Interleukin-13 is expressed in mouse Kidney allograft rejection and mediates proliferation of renal tubular epithelium *in vitro*. *Journal of Epithelial Biology and Pharmacology* 2008; 1:8-15.
54. Matas AJ, Leduc R, Rush D, Cecka JM, Connett J, Fieberg A, Halloran P, Hunsicker L, Cosio F, Grande J, **Mannon R**, Gourishanker S, Gaston R, Kasiske B. Histopathologic clusters predict graft survival better than current nonspecific diagnoses of CAN or CR: Data from the DeKAF study. *American Journal of Transplantation*, 2010; 10:315-323.
55. Gourishankar S, Leduc R, Connett J, Cecka JM, Cosio F, Fieberg A, Gaston R, Halloran P, Hunsicker L, Kasiske B, Rush D, Grande J, **Mannon R**, Matas A. Pathological and clinical characterization of the "troubled transplant": Data from the DeKAF Study. *American Journal of Transplantation*, 2010; 10:324-330.
56. Sis, B, Mengel M, Haas M, Colvin RB, Philip F. Halloran PF, Racusen LC, Solez K, Broecker V, Baldwin III WM, Bracamonte ER, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, **Mannon RB**, Matas A, Nankivell BJ, Nickleleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Surya S, Stegall M, Suthanthiran M, Wasowska B, Zachary A, Zeevi A. Banff '09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups. *American Journal of Transplantation* 2010; 10:464-471.
57. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Connett J, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, **Mannon R**, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. *Transplantation* 2010, 90: 68-74.
58. Elster EE, Hawksworth JS, Cheng O, Leiser DB, Ring M, Tadaki DK, Kleiner DE, Eberhardt III JS, Brown TS, **Mannon RB**. Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy. *The Journal of Molecular Diagnostics*, 2010, 12(5): 653-663.
59. Cravedi P, Maggiore U, **Mannon RB**. The role of low density array PCR analysis of reperfusion biopsies: Insights into kidney allograft outcomes. *Nephrology Dialysis Transplantation*, 2010, 25(12): 4077-4086.
60. Cho M, Duan Z, Wright EC, Chamberlain CE, Reynolds JC, Ring MS, **Mannon RB**. Cincalcet improves bone density in post kidney transplant hyperparathyroidism. *Transplantation Proceedings*, 2010, 42(9): 3554-3558.
61. Hon YY, Chamberlain CE, Kleiner DE, Ring MS, Hale DA, Kirk AD, **Mannon RB**. Evaluation of Tacrolimus Abbreviated Area-Under-the-Curve Monitoring in Renal Transplant Patients Who Are Potentially At Risk for Adverse Events. *Clinical Transplantation*, 2010; 24: 557-563.
62. **Mannon RB**, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, Cecka JM, Gaston RS, Cosio F, Gourishankar S, Halloran P, Hunsicker L, Rush D. Inflammation in Areas of Tubular Atrophy in Kidney Allograft Biopsies: A Potent Predictor of Allograft Failure. *American Journal of Transplantation*, 2010, 10: 2066-2073.
63. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Israni A, Leduc R, Holmes J, Jacobson PA, Lamba V, Guan W, Schladt D, Chen J, Matas AJ, Oetting WS; **DeKAF Investigators**. *Transplantation*. 2010; 90:1401-1408.
64. Asico L, Zhang X, Jiang J, Cabrera D, Escano CS, Sibley DR, Wang X, Yang Y, **Mannon R**, Jones JE, Armando I, Jose PA. Lack of renal dopamine D5 receptors promotes hypertension. *Journal of the American Society of*

- Nephrology 2011; 22: 82-89.
65. Crary GS, Raissian Y, Gaston RC, Gourishankar SM, Leduc RE, **Mannon RB**, Matas AJ, Grande JP. Optimal Cutoff Point for Immunoperoxidase Detection of C4d in the Renal Allograft: Results From a Multicenter Study. *Transplantation* 2010; 90:1099-1105.
 66. Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D, Matas AJ, Lamba V, Julian BA, **Mannon RB**, Israni A; for DeKAF Investigators. Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium. *Transplantation* 2011; 91:300-308.
 67. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Lamba V, **Mannon RB**, Julian B, and Israni A. Genetic Determinants of Mycophenolate Related Anemia and Leukopenia Following Transplantation. *Transplantation* 2011; 91:309-316.
 68. Srivastava M, Eidelman O, Torosyan Y, Jozwik C, **Mannon RB**, Pollard HB. Elevated Expression Levels of ANXA11, Integrins $\beta 3$ and $\alpha 3$, and TNF α Contribute to a Candidate Proteomic Signature in Urine for Kidney Allograft Rejection. *Proteomics-Clinical Applications* 2011; 5:311-321..
 69. Karp SJ, **Mannon RB**. What's New, What's Hot in Solid Organ Transplantation? Summary of the American Transplant Congress 2011. *American Journal of Transplantation* 2011, 11(11): 2308-2316.
 70. Sam W-J, Chamberlain CE, Lee S-J, Goldstein JA, Hale DA, **Mannon RB**, Kirk AD, Hon YY. Associations of *ABCB1* 3435C>T and *IL-10* -1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. *Transplantation* 2011; 92: 1342-1347. PMID 22094953.
 71. Jacobson PA, Schladt D, Israni A, Oetting WS, Lin YC, Leduc R, Guan W, Lamba V, Matas AJ; **DeKAF Investigators**. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. *Transplantation*. 2012 Mar 27;93(6):624-31.
 72. Zarjou A, Guo L, Sanders PW, **Mannon RB**, Agarwal A, George JF. A reproducible mouse model of chronic allograft nephropathy with vasculopathy. *Kidney Int.* 2012; 82(11):1231-5. PMID:22874842
 73. Randhawa P, **Mannon RB**. A Case of Late Kidney Allograft Failure: A Clinical Pathological Conference from ASN Kidney Week 2011. *Clin J Am Soc Nephrol.* 2012;7(11):1884-9. PMID 22859745.
 74. Sam WJ, Chamberlain CE, Lee SJ, Goldstein JA, Hale DA, **Mannon RB**, Kirk AD, Hon YY. Associations of *ABCB1* and *IL-10* Genetic Polymorphisms With Sirolimus-Induced Dyslipidemia in Renal Transplant Recipients. *Transplantation*. 2012; 94(9):971-977. PMID 23073467.
 75. Keslar KS, Lin M, Zmijewska AA, Sigdel TK, Tran TG, Ma L, Bhasin M, Rao P, Ding R, Ikle DN, **Mannon RB**, Sarwal MM, Strom T, Reed EF, Heeger PS, Suthanthiran M, Fairchild RL. A Standardized Protocol for Non-Invasive Gene Expression Profiling in Multi-Center Clinical Trials. *American Journal of Transplantation* 2013, 13: 1891-1897. PMID 23802725.
 76. Van Gelder T, Baan C, Vincente F, **Mannon RB**. Report of the Second Joint Meeting of ESOT and AST: Transformational Therapies and Diagnostics in Transplantation. *Transplantation International* 2013; 26(9):938-48. PMID: 23822608.
 77. Locke JE, James N, **Mannon RB**, Mehta SG, Pappas P, Baddley J, Desai NM, Montgomery RA, Segev DL. Immunosuppression Regimen and the Risk of Acute Rejection in HIV-infected Kidney Transplant Recipients. *Transplantation*. 2013 Oct 24. [Epub ahead of print]. PMID: 24162248
 78. Alegria, M-L, **Mannon RB**, Mannon PJ. The Microbiota, the Immune System and the Allograft. *American Journal of Transplantation*, 2014; 14(6):1236-48. PMID: 24840316.
 79. Aggarwal H, AlJaroudi WA, Mehta S, **Mannon R**, Heo J, Iskandrian AE, Hage FG. The Prognostic Value of Left Ventricular Mechanical Dyssynchrony using Gated Myocardial Perfusion Imaging in Patients with End-Stage-Renal-Disease. *Journal of Nuclear Cardiology. J Nucl Cardiol.* 2014;21(4):739-46. PMID: 24858622.
 80. Chen J, Zmijewska A, Zhi D, **Mannon RB**. Cyclosporine-Associated Allograft Fibrosis is Associated with Micro-RNA 21 Through AKT Signaling. *Transplant International* 2015; 28(2): 232-245. PMID 25266172.
 81. Srivastava M, Torosyan Y, Eidelman O, Jozwik C, Pollard HB, **Mannon R**. Reduced PARP1 as a Serum Biomarker for Graft Rejection in Kidney. *Journal of Proteomics and Bioinformatics* 2015; 8: 31-38. PMID:
 82. Locke JE, Qu H, Shewchuk R, **Mannon RB**, Gaston R, Segev DL, Mannon EC, Martin MY. Identification of Strategies to Facilitate Organ Donation among African Americans using the Nominal Group Technique. *Clin J Am Soc Nephrol.* 2015 Feb 6;10(2):286-93. PMID: 25635038
 83. Locke JE, Reed RD, Mehta SG, Durand C, **Mannon RB**, MacLennan P, Shelton B, Martin M, Qu H, Shewchuk R, and Segev DL. Center-level Experience and Kidney Transplant Outcomes in HIV-infected Recipients. *American Journal of Transplantation*, 2015. *American Journal of Transplantation* 2015; 15: 2096-2104. PMID: 2577349.
 84. Donnelly JP, Wang HE, Locke JE, **Mannon RB**, Safford MM, Baddley JW. Hospital onset *Clostridium difficile* infection among solid organ transplant recipients. *American Journal of Transplantation* 2015;15(11):2970-7. PMID: 26484839.
 85. Oetting WS, Schladt DP, Guan W, Miller MB, Rimmel R, Don C, Sanghavi K, **Mannon RB**, Herrera B, Matas AJ, Salomon DR, Kwok P-Y, Keating BK, Israni AK, Jacobson PA. Genome wide association study of tacrolimus

- concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles. *American Journal of Transplantation* 2016 16(2):574-82. PMID: 26485092
86. Wolf M, Weir MR, Kopyt N, **Mannon RB**, Von Visgar J, Deng H, Yue S, Vincenti F. A Prospective Cohort Study of Mineral Metabolism Following Kidney. *Transplantation* 2016; 100(1):184-193. PMID: 26177089
 87. Stegall M, Morris R, Alloway R, **Mannon RB**. Developing new immunosuppression for the next generation of transplant recipients: The path forward. *American Journal of Transplantation* 2016; 16(4): 1094-2101. PMID: 26730885
 88. Jacobson P, Sanghavi K, Brundage R, Miller M, Schladt D, Israni A, Guan W, Oetting W, **Mannon R**, Rimmel R, Matas A. Genotype-guided tacrolimus dosing in African American kidney transplant recipients. *The Pharmacogenomics Journal*. PMID: 26667830.
 89. Donnelly JP, Locke JE, MacLennan P, McGwin Jr. G, **Mannon RB**, Safford MM, Baddley JW, Muntner PM, Wang HE. Inpatient Mortality among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis. *Clinical Infectious Diseases* 2016; 63(2):186-94. PMID 27217215.
 90. Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, **Mannon RB**, Rimmel RP, Matas AJ, Jacobson PA. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. *Pharmacogenomics J*. 2017 Jan;17(1):61-68. PMID: 26667830
 91. Locke JE, Reed RD, Massie A, MacLennan PA, Sawinski D, Kumar V, Mehta S, **Mannon RB**, Gaston R, Lewis CE, Segev DL. Obesity and end-stage renal disease risk among living kidney donors. *Kidney International* 2017 Mar;91(3):699-703. PMID 28041626.
 92. Locke JE, Mehta S, Sawinski D, Gustafson S, Shelton BA, Reed RD, MacLennan P, Bolch C, Durand C, Massie A, **Mannon RB**, Gaston R, Saag M, Overton T, Segev DL. Access to Kidney Transplantation among HIV-infected Waitlist Candidates. *Clinical Journal of the American Society of Nephrology* 2017 Mar 7;12(3):467-475, PMID 28232406.
 93. Gordon EJ, Sohn M-W, Chih-Hung C, McNatt G, Vera K, Beauvais N, **Mannon RB**, Ison MG. A Mobile App to Inform Transplant Candidates about Increased Risk Donor Kidneys: A Randomized Controlled Trial of Increased Knowledge. *Transplantation* 2017; 101(6):1167-76. PMID 27463536.
 94. Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, **Mannon RB**, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. *J Am Soc Nephrol*. 2017 Jul;28(7):2221-2232. PMID: 28280140.
 95. O'Connell PJ, Kuypers D, **Mannon RB**, Abecassis M, Chadban S, Gill JS, Lemery S, Murphy B, Nickerson PW, Schold JD, Stock P, Seron D, Alloway R, Bromberg J, Budde K, Jordan S, Legendre C, Lefaucher C, Sarwal M, Segev D, Stegall MD, Tullius S, Wong G, Woodle S, Ascher N, Morris RE. Clinical trials for immunosuppression in transplantation: The case for reform and change in direction. *Transplantation*. 2017 Jul;101(7):1527-1534. PMID: 28207630.
 96. Newell KA, Mehta AK, Larsen CP, Stock PG, Farris AB, Mehta SG, Ikle D, Armstrong B, Morrison Y, Bridges N, Robien M, Tomlin N, **Mannon RB**. Lessons learned: Early termination of a randomized trial of calcineurin inhibitor and corticosteroid avoidance using Belatacept. *American Journal of Transplantation* 2017; 17(10):2712-2719. PMID: 28556519.
 97. Asare A, Kanaparthi S, Lim N, Vincenti F, Stock P, Friedewald J, Pavlakis M, Poggio E, Heeger P, **Mannon RB**, Burrell B, Morrison Y, Bridges N, Sanz I, Chandraker A, Newell KA, Turka LA. B Cell Receptor Genes Associated with Tolerance Identify a Cohort of Immunosuppressed Patients with Improved Renal Allograft Graft Function. *American Journal of Transplantation*, 2017. *Am J Transplant*. 2017; 17(10): 2627-2639. PMID: 28371372.
 98. Bromberg JS, Brennan DC, Poggio E, Bunnapradist S, Langone A, Sood P, Matas AJ, **Mannon RB**, Mehta S, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen DJ, Zaky ZS, Hiller DG, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Bloom RD. Biological Variation of Donor-derived Cell-free DNA in Renal Transplant Recipients: Clinical Implications. *Journal of Applied Laboratory Medicine* 2017; 2(3): 309-321. PMID:
 99. Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Van Huyen J-P D, Lefaucheur C, Malone A, **Mannon RB**, Seron D, Sellares J, Weir M, Loupy A. Real time central assessment of kidney transplant indication biopsies by microarrays: The INTERCOMEX Study. *Am J Transplant*. 2017 Nov;17(11):2851-2862. doi: 10.1111/ajt.14329. PMID: 28449409.
 100. M Haas, A Loupy, C Lefaucheur, C Roufoss, D Glotz, D Seron, B J Nankivell, P F Halloran, R B Colvin, S. Bagnasco, J U Becker, L Cornell, J P Duong, I Gibson, **RB Mannon**, M Naesens, V Nickeleit, P Nickerson, D Segev, HK Singh, M Stegall, P Randhawa, L Racusen, K Solez, M Mengel. The Banff 2017 Kidney Meeting Report: Revised Diagnostic Criteria for Chronic, Active T Cell-Mediated Rejection and Antibody-Mediated Rejection. *American Journal of Transplantation*, 2018. Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21. PMID: 29243394.

101. Locke JE, Sawinski D, Reed RD, Shelton B, MacLennan PA, Kumar V, Mehta S, **Mannon RB**, Gaston R, Julian B, Carr JJ, Terry JG, Kilgore M, Massie AB, Segev DL, Lewis CE. APOL1 genotyping and kidney failure risk projection for the young living kidney donor candidate. *Ann Surg*. 2018 Jun;267(6):1161-1168. PMID: 28187045
102. Oetting WS, Baolin Q, Schladt DP, Guan W, Remmel RP, Dorr C, **Mannon RB**, Matas AJ, Israni AK, Jacobson PA for the DeKAF Genomics Investigators. Attempted Validation of 44 Previously Reported SNPs Associated with Tacrolimus Troughs using a Large Cohort of Kidney Allograft Recipients. *Pharmacogenomics*. 2018 Feb;19(3):175-184. PMID: 29318894.
103. Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, **Mannon RB**, Matas AJ, Israni AK, Jacobson PA. Genome wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients. *Pharmacogenomics J*. 2018 May 22;18(3):501-505. PMID: 29160300.
104. Gaston RS, Fieberg A, Hunsicker L, Kasiske BL, Leduc R, Cosio FG, Gourishankar S, Grande J, **Mannon RB**, Rush D, Cecka JM, Connett J, Matas AJ. Late graft failure after kidney transplantation as a consequence of late versus early events. *Am J Transplant*. 2018 May;18(5):1158-1167. PMID: 29139625.
105. Snoek R, Van Setten J, Keating BJ, Israni AK, Jacobson PA, Oetting WS, Matas AJ, **Mannon RB**, Zhang Z, Zhang W, Hao K, Murphy B, Reindl-Schwaighofer R, Heinz A, Oberbauer R, Viklicky O, Stapleton C, Bakker SLJ, Snieder H, Peters EDJ, van der Zwaag B, Knoers NVAM, de Borst MH, van Eerde AM. NPHP1 gene deletions cause adult onset end stage renal disease. *Journal of the American Society of Nephrology* 2018; Jun;29(6):1772-1779. PMID 29654215.
106. Tambur AR, Campbell P, Class FH, Feng S, Gebel HM, Jackson AM, **Mannon RB**, Reed EF, Tickam K, Askar M, Change P, Colvin M, Demetris J, Diamond J, Dipchand A, Fairchild R, Ford M, Friedewald J, Gill R, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine D, Levitsky J, Mengel M, Milford E, Newell K, O'Leary J, Palmer S, Randhawa P, Smith J, Snyder L, Starling R, Sweet S, Taner T, Taylor C, Woodle S, Zeevi A, Nickerson P. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. *American Journal of Transplantation*, 2018 Jul;18(7):1604-1614. PMID 29603613.
107. Seibert S, Schladt D, Wu B, Guan W, Corr C, Matas A, **Mannon R**, Israni A, Oetting W, Jacobson P. Tacrolimus Trough and Dose Intra-Patient Variability and CYP3A5 Genotype: Effects on Acute Rejection and Graft Failure in European American and African American Kidney Transplant Recipients. *Clin Transplant*. 2018 Oct 14:e13424. doi: 10.1111/ctr.13424. [Epub ahead of print]. PMID: 30318646.
108. Rangarajan S, Bone NB, Zmijewska AA, Jiang S, Won-Park D, Bernard K, Locy ML, Ravi S, Deshane J, **Mannon RB**, Darley-Usmar V, Thannickal VJ, Zmijewski JW. Metformin reverses established lung fibrosis in a bleomycin model. *Nat Med*. 2018 Aug;24(8):1125-1131. doi: 10.1038/s41591-018-0087-6. Epub 2018 Jul 2. . *Nat Med*. 2018 Aug;24(8):1121-1127. doi: 10.1038/s41591-018-0087-6. Epub 2018 Jul 2. Erratum in: *Nat Med*. 2018 Oct;24(10):1627. PMID: 29967351.
109. Mundra VRR and **Mannon RB**. Nephrology Quiz and Questionnaire 2017: Transplantation. *Clin J Am Soc Nephrol*. 2018 Aug 7;13(8):1251-1253. doi: 10.2215/CJN.00020118. Epub 2018 Jul 24. PMID 30042222.
110. Tong A, Sautenet B, Poggio E, Lentine K, Oberbauer R, **Mannon RB**, Murphy B, Padilla B, Chow KM, Marson L, Chadban S, Craig JC, Ju A, Manera KE, Hanson CS, Josephson MA, Knoll G, on behalf of the SONG-Tx Graft Health Workshop Investigators*. Establishing a Core Outcome Measure for Graft Health: a Standardized Outcomes in Nephrology – Kidney Transplantation (SONG-Tx) Consensus Workshop Report. *Transplantation*. 2018 Aug;102(8):1358-1366. doi: 10.1097/TP.0000000000002125. PMID: 29470347.
111. Seifert ME, Yanik MV, Feig DI, Hauptfeld-Dolejssek V, Mroczek-Musulman EC, Kelly DR, Rosenblum F, **Mannon RB**. Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation. *Am J Transplant*. 2018 Sep;18(9):2189-2199. doi: 10.1111/ajt.14933. Epub 2018 Jun 27. PMID: 29766640
112. **Mannon RB**, Askar M, Jackson AM, Newell K, Mengel M. Meeting Report of the STAR – Sensitization in Transplantation Assessment of Risk: Naïve Abdominal Transplant Organ Subgroup Focus on Kidney Transplantation. *Am Jnl of Transplantation* 2018; 18(9): 2120-2134. PMID: 29943908.
113. Lan J, Gjeertson D, Zheng Y, Clark S, Gaston R, **Mannon R**, Kasiske B, Matas A, Leduc R, Connett J, Fieberg A, Grande J, Cosio F, Gourishankar S, Hunsicker L, Rush, D, Reed E, Cecka M. Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. *American Journal of Transplantation*, Dec;18(12):2934-2944. doi: 10.1111/ajt.14871. Epub 2018 May 9. PMID: 29659162
114. First MR, Peddi VR, **Mannon RB**, Knight R, Marsh CL, Kurian SM, Rice JC, Maluf D, Mandelbrot D, Patel A, David J, Schieve C, Lee D, Lewis P, Friedewald JJ, Abecassis MA, Rose S. Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice. *Transplantation Proceedings* 2019, 51, 729-733. PMID 30979457.
115. Stegall MD, Somerville KT, Everly M, **Mannon RB**, Gaber, OA, First MR, Agashivala N, Perez V, Newell KA, Morris RE, Sudan D, Romero K, Eremenco S, Matera M, Spear N, Porter AC, O'Doherty I. The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients: The Transplant

- Therapeutics Consortium's Position Statement. *American Journal of Transplantation*, 2019, Mar;19(3):625-632. doi: 10.1111/ajt.15214. Epub 2019 Jan 23. PMID: 30549395.
116. Marsh CL, Kurian SM, Rice JC, Whisenant, TC, David J, Rose S, Schieve C, Lee D, Case J, Barrick B, Peddi VR, **Mannon RB**, Knight R, Maluf D, Mandelbrot D, Patel A, Friedewald JJ, Abecassis MM, First MR. Application of TruGraf® v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients with Stable Renal Function. *Transplantation Proceedings*, 2019 Apr; 51(3): 722-728, PMID 30979456.
 117. Matas AJ, Fieberg A, **Mannon RB**, Leduc R, Grande J, Kasiske BL, Cecka JM, Gaston RS, Hunsicker L, Connett J, Cosio F, Gourishankar S, Rush D. Long-term Follow-up of the DeKAF Cross-Sectional Cohort Study. Accepted for publication, *Am Jnl Transplant*, 2019. May;19(5):1432-1443. doi: 10.1111/ajt.15204. Epub 2019 Jan 24. PMID: 30506642.
 118. Agarwal G, **Mannon RB**. Nephrology Quiz and Questionnaire: Post Transplant Lymphoproliferative Disease. *Clin J Am Soc Nephrol*. 2019 May 7;14(5):751-753. doi: 10.2215/CJN.00180119. Epub 2019 Feb 25. No abstract available. PMID: 30803963.
 119. Oetting WS, Baolin W, Schladt DP, Guan W, van Setten J, Keating B, Ikle D, Remmel RP, Dorr CR, **Mannon RB**, Matas AJ, Israni AK, Jacobson PA for the DeKAF Genomics Investigators. Genetic Variants Associated with Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome Wide Association Studies. *Transplantation*, 2019, June 103(6): 1131-1139, PMID: 30801552.
 120. Oetting WS, Schladt DP, Dorr C, Wu B, Guan W, Remmel RP, Ikle D, **Mannon RB**, Matas A, Israni AK, Jacobson PA. Analysis of 75 Candidate SNPs Associated with Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. *Transplantation*. 2019 Aug;103(8):1591-1602. 2019 Feb 11. doi: 10.1097/TP.0000000000002659. [Epub ahead of print]. PMID: 30801535.
 121. Dorr DR, Baolin W, Remmel RP, Muthusamy A, Schladt DP, Abrahante JE, Guan W, **Mannon RB**, Matas AJ, Oetting WS, Jacobson PA, Israni AK. Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. *The Pharmacogenomics Journal*, 2019 Aug;19(4):375-389. 2018, Nov 16. doi: 10.1038/s41397-018-0063-z. [Epub ahead of print]. PMID: 30442921.
 122. Stapleton CP, Heinzl A, Guan W, Van der Most PJ, Van Setten J, Lord GM, Keating BJ, Israni AK, de Borst MH, Bakker SJL, Snieder H, Weale ME, Delaney F, Hernandez-Fuentes MP, Reindl-Schwaighofer R, Oberbauer R, Jacobson PA, Mark PB, Chapman FA, Pehlan PJ, Kennedy C, Sexton D, Murray S, Jardine A, Traynor JP, McKnight AM, Maxwell AP, Smyth LJ, Oetting WS, Matas AJ, **Mannon RB**, Schladt DP, Ikle DN, The UK and Ireland Renal Transplant Consortium, DeKAF Genomics and GEN03 Studies, The International Genetics and Translational Research in Transplantation Network, Cavalieri GL, and Conlon PJ. The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. *Am Jnl Transplant* 2019; 19(8):2262-2273. DOI:10.1111/ajt.15326. PMID: 30920136
 123. Seifert ME, Gaut JP, Guo B, Jain S, Malone AF, Geraghty F, Della Manna D, Yang ES, Yi N, Brennan DC, **Mannon RB**. WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure. *Am J Transplant* 2019; 19(10):2833-2845; 2019 Mar 27. doi: 10.1111/ajt.15372. [Epub ahead of print]. PMID: 30916889.
 124. Mohamed ME, Schladt DP, Guan W, Wu B, Van Setten J, Keating B, Ikle D, Remmel RP, Dorr CR, **Mannon RB**, Matas AJ, Israni AK, Oetting WS, Jacobson PA. Tacrolimus Troughs and Genetic Determinants of Metabolism in Kidney Transplant Recipients: A comparison of four ancestry groups. *American Journal of Transplantation* 2019 Oct;19(10):2795-2804. PMID: 30953600.
 125. Yanik MV, Seifert M, Locke J, Hauptfeld-Dolejssek V, Crowley M, Cutter G, **Mannon RB**, Feig DI, Limdi NA. CYP3A5 Genotype Affects Time to Therapeutic Tacrolimus Level in Pediatric Kidney Transplant Recipients.. *Pediatr Transplant*. 2019 May 24:e13494. doi: 10.1111/petr.13494. [Epub ahead of print]. PMID: 31124575. *Pediatric Transplantation* 2019. PMID: 31124575. PMID: 31096218.
 126. Schinstock CA*, **Mannon RB***, Budde K, Chong AS, Haas M, Knechtle S, Lefaucheur C, Montgomery R, Nickerson P, Tullius SG, Ahn C, Askar M, Crespo M, Chadban SJ, Feng S, Handan O, Jordan S, Kwan NM, Mengel M, Morris R, O'Doherty I, Seron D, Tambur A, Tanabe K, Jean-luc Taupin J-L, O'Connell PJ. Recommended Treatment for Antibody Mediated Rejection: Expert Consensus from The Transplant Society Working Group. *Transplantation*, 2020 May;104(5):911-922. doi: 10.1097/TP.0000000000003095.. PMID: 31895348. PMCID: PMC7176344
 127. Young CJ, Hanaway M, Mannon EC, Deierhoi RR, MacLennan P, Shelton B, Agarwal G, Gaston RS, Julian B, Kew C, Kumar V, **Mannon RB**, Mehta S, Ong S, Towns G, Hayles H, Deierhoi D, Goodman J, Locke JL. Redefining the influence of ethnicity on simultaneous kidney and pancreas transplantation outcomes: a 15 year single center experience. *Ann Surg* 2020 Jan;271(1):177-183. doi: 10.1097/SLA.0000000000002816. PMID: 29781845
 128. Crosland W, Aggarwal H, Farag A, Mehta S, **Mannon RB**, Heo J, Iskandrian AE, Hage FG. The effect of renal transplantation on left ventricular function, electrocardiography, and mechanical synchrony by gated myocardial perfusion imaging. *J Nucl Cardiol* 2019 Dec;26(6):1962-1970. doi: 10.1007/s12350-018-1411-8. Epub 2018 Oct 22PMID: 30350267.

129. Freedman BI, Moxey-Mims MM, Alexander AA, Astor BC, Birdwell KA, Bowden DW, Bowen G, Bromberg J, Craven TE, Dadhania DM, Divers J, Doshi MD, Eidbo E, Fornoni A, Gautreaux MD, Gbadegesin RA, Gee PO, Guerra G, Hsu CY, Iltis AS, Jefferson N, Julian BA, Klassen DK, Koty PP, Langefeld CD, Lentine KL, Ma L, **Mannon RB**, Menon MC, Mohan S, Moore JB, Murphy B, Newell KA, Odum J, Ortigosa-Goggins M, Palmer ND, Park M, Parsa A, Pastan SO, Poggio ED, Rajapakse N, Reeves-Daniel AM, Rosas SE, Russell LP, Sawinski D, Smith SC, Spainhour M, Stratta RJ, Weir MR, Reboussin DM, Kimmel PL, Brennan DC. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. *Kidney Int Rep.* 2019 Dec 13;5(3):278-288. doi: 10.1016/j.ekir.2019.11.022. eCollection 2020 Mar. PMID: 32154449 PMC7056916.
130. Stock PG, **Mannon RB**, Armstrong B, Watson, N, Ikle D, Robien M, Morrison Y, Odorico O, Fridell J, Mehta AK, Newell KA. Challenges of Calcineurin Inhibitor Avoidance Following Combined Pancreas and Kidney Transplantation. *Am J Transplant* 2020 Jun;20(6):1668-1678. doi: 10.1111/ajt.15817. Epub 2020 Mar 8. PMID: 32039559.
131. **Mannon RB**, Morris RE, Abecassis M, Axelrod D, Bala S, Friedman GS, Heeger PS, Lentine KL, Loupy A, Murphy B, Nickerson P, Sarwal M, O'Doherty I, Spear N, Karpen SR. Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report. *Am J Transplant* 2020 Jun;20(6):1495-1502. doi: 10.1111/ajt.15833. Epub 2020 Mar 17. PMID: 32090461.
132. Ong SC, **Mannon RB**. Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer. *Clin J Am Soc Nephrol.* 2020 Aug 7;15(8):1190-1192. PMID: 32205320.
133. Matas A, Helgeson E, Gaston R, Cosio F, **Mannon R**, Kasiske B, Hunsicker L, Gourishanker S, Rush D, Cecka M, Connett J, Grande J. Inflammation in Areas of Fibrosis: The DeKAF Prospective Cohort. *Am J Transplant* 2020; 20(9): 2509-2521. Mar 17. doi: 10.1111/ajt.15862. PMID: 32185865.
134. Loupy A, Haas M, Roufosse C, Naessens M, Adam B, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell L, Clahsen-Van Groningen MC, Demetris J, Dragun D, Duong van Huyen JP, Farris AB, Fogo A, Glotz D, Gueguen J, Kraus E, Leflaucheur C, **Mannon RB**, Montgomery R, Nankivell BJ, Nickleit V, Nickerson P, Rabant M, Racusen L, Randhawa P, Robin B, Schinstock CA, Seron D, Singh HK, Stegall M, Zeevi A, 14, K. Solez K, Colvin RB27, Mengel M. The Banff 2019 Kidney Meeting Report: Updates on T Cell- and Antibody-Mediated Rejection, and Adoption of a Banff Consensus Gene Set for Multiorgan Transplant Diagnostics. [published online ahead of print, 2020 May 28]. *Am J Transplant.* 2020;20(9): 2318–2331. doi:10.1111/ajt.15898. PMID: 3246318.
135. Tambur AR, Campbell P, Chong AS, Fend S, Ford ML, Gebel H, Gill RG, Kelsoe G, Kosmoliaptsis V, **Mannon RB**, Mengel M, Reed EF, Valenzuela NM, Wiebe C, Dijke EI, Sullivan HC, Nickerson P. Sensitization in Transplantation: Assessment of Risk (STAR) 2019 Working Group Meeting Report. *Am J Transplant* 2020 20(10):2652-2668. doi: 10.1111/ajt.15937. PMID: 32342639.
136. Lentine K, Vest K, Schnitzler M, **Mannon RB**, Kumar V, Doshi M, Cooper M, Mandelbrot D, Harhay M, Josephson MA, Caliskan Y, Sharfuddin A, Kasiske B, Axelrod D. Survey of U.S. Living Kidney Donation and Transplant Practices in the COVID-19 Era. *Kidney International Reports*, 2020 Nov; 5(11); 1894-1905. PMID: 32864513. PMC7445484.
137. Lentine KL, Peipert J, Alhamad T, Caliskan Y, Concepcion B, Forbes R, Schnitzler M, Chang S-H, Cooper M, Bloom R, **Mannon RB**, Axelrod D, Survey of Clinician Opinions on Use of Kidney Transplants from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. *Kidney* 360 2020; Nov 1(11): 1291-1299. PMC7695231.
138. Nguyen TT, Pearson RA, Mohamed ME, Schladt DP, Berglund D, Rivers Z, Skaar DJ, Wu B, Guan W, Van Setten J, Keating BJ, Dorr C, Rimmel RP, Matas AJ, **Mannon RB**, Israni AK, Oetting WS, Jacobson PA. Actionable Pharmacogenomics in Kidney Transplant Recipients and Potential for Integration into Practice. *J Clin Pharm Ther.* 2020 Dec;45(6):1457-1465. PMID: 32662547
139. **Mannon RB**, Armstrong B, Stock PG, Mehta AK, Farris AB, Watson N, Morrison Y, Bridges N, Robien M, Newell KA, Larsen CP. Avoidance of CNI and Steroids Using Belatacept-Results of the Clinical Trials in Organ Transplantation 16 Trial. [Published online ahead of print, 2020 Jun 18]. *Am J Transplant.* 2020 Dec;20(12):3599-3608 doi:10.1111/ajt.16152 PMID: 32558199.
140. Ang A, Schieve C, Rose S, Kew C, First MR, **Mannon RB**. Avoiding Surveillance Biopsy: Use of noninvasive biomarker assay in a real-life scenario. *Clinical Transplantation.* 2021 Jan;35(1):e14145. doi: 10.1111/ctr.14145. Epub 2020 Nov 24. PMID: 33170974.
141. Seifert ME, Agarwal G, Bernard M, Kasik E, Sikandar R, Fatima H, Gaston RS, Hauptfeld-Dolesjek V, Julian BA, Kew CE, Kumar V, Mehta S, Ong S, Rosenblum S, Towns G, **Mannon RB**. Impact of subclinical borderline inflammation on kidney transplant outcomes. *Transplant Direct.* 2021 Jan 26;7(2):e663. doi: 10.1097/TXD.0000000000001119. eCollection 2021 Feb. PMID: 33511268 PMCID: PMC7837932.
142. Helgeson E, **Mannon RB**, Grande J, Gaston RS, Cecka M, Kasiske B, Rush D, Gourishankar S, Cosio F, Hunsicker L, Matas AJ. i-IFTA and Chronic Active T-Cell Mediated Rejection: A Tale of 2 (DeKAF) Cohorts. *Am J Transplant.* 2021 May;21(5):1866-1877. doi: 10.1111/ajt.16352. Epub 2020 Nov 8. PMID: 33052625.

143. Al-Kofahi M, Oetting WS, Schladt DP, Remmel RP, Guan W, Wu B, Dorr CR, **Mannon RB**, Matas AJ, Israni AK, Jacobson, PA. Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. *Journal of Clinical Pharmacology*. 2021; Aug 61(8): 1035-1044. PMID: 33512723.
144. Harhay, MN, Klassen A, Zaidi H, Mittelman M, Bertha R, **Mannon RB**, Lentine KL. Living Organ Donor Perspectives and Sources of Hesitancy about COVID-19 Vaccines. *Kidney360*, 2: 1132-1140. PMID: 34337426 PMCID: PMC8323843.
145. Wolf-Doty TK, **Mannon RB**, Poggio ED, Hinojosa RJ, Hiller D, Bromberg JS, Brennan, DC. Donor-Derived Cell Free DNA is a Dynamic Biomarker in Response to Treatment of Acute Rejection in Kidney Allografts. *Kidney360* April 2021, 2 (4) 729-736; DOI: <https://doi.org/10.34067/KID.0000042021>.
146. Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Shirazian S, Khairallah P, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusano A, Blosser C, Zuniga S, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, **Mannon RB**, Shirai K, Kitchlu A, Ong S, Machado SA, Mothi SS, Ott P, Rahma O, Hodi S, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Vinay V, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Leonardo V, Riella LV, Kenar D, Jhaveri KD On behalf of Immune Checkpoint Inhibitor in Solid Organ Transplant Consortium. Use of immune checkpoint inhibitors in kidney transplant recipients: a multi-center study. *Kidney Int*. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24. PMID: 33359528 PMCID: PMC8222056.
147. Sun J, Patel RC, Zheng Q, Madhira V, Olex AL, Islam JY, French E, Chiang T P-Y, Akselrod H, Moffitt R, Alexander C, Andersen KM, Vinson AJ, Brown TT, Chute CG; Crandall KA; Franceschini N; **Mannon RB**, Kirk GD. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally representative, Multicenter, Observational Cohort Study. *medRxiv*. 2021 Jul 28;2021.07.26.21261028. doi: 10.1101/2021.07.26.21261028. Preprint. PMID: 34341798 PMCID: PMC8328066.
148. Zmijewska AA, Zmijewski JA, Benavides GA, Darley-Usmar V, and **Mannon RB**. Bioenergetic Maladaptation and Release of HMGB1 in Calcineurin Inhibitor Nephrotoxicity. Feb 28 2021. *Am J Transplant*. 2021 Mar 16. doi: 10.1111/ajt.16561. Online ahead of print. 2021 Sep;21(9):2964-2977. doi: 10.1111/ajt.16561. Epub 2021 Apr 2. PMID: 33724664 PMID: 33724664. PMCID: PMC8429074.
149. Lentine KL, Singh N, Woodside KJ, Schnitzler MA, Li R, Alhamad T, Rothweiler R, Parsons RF, **Mannon RB**, Snyder J, Cooper M, Axelrod D. COVID-19 Test Reporting for Deceased Donors: Emergent Policies, Logistical Challenges and Future Directions. *Clin Transplant*. 2021 May;35(5):e14280. doi: 10.1111/ctr.14280. Epub 2021 Mar 25. PMID: 33690910 PMCID: PMC8206716.
150. Kim Y, Ahmed E, Ascher N, Danguilan R, Hooi LS, Hustrini NM, Kim YH, Kute V, Rosete-Liquete RMO, Ma M, **Mannon RB**, Nakagawa Y, Od-Erdne L, Ramesh V, Rashid HU, Thangaraju S, Thwin KT, Vathsala A, West L, Win KK, Ahn C, Wong G. Meeting Report: First State of the Art Meeting on Gender Disparity in Kidney Transplantation in the Asia-Pacific. *Transplantation*. 2021 Sep 1;105(9):1888-1891. doi: 10.1097/TP.0000000000003841. PMID: 34416749.
151. Lentine KL, Jones C, Cheungpasitporn W, Rothweiler R, Xiao H, Marklin G, Ortigosa-Goggins M, Schnitzler MA, Cooper M, **Mannon RB**. Disparities in Deceased Organ Donor Research Authorization: Experience at One Organ Procurement Organization and Call for National Conversations. *Kidney Int Rep*. 2021 Jun 26;6(9):2331-2337. doi: 10.1016/j.ekir.2021.06.017. eCollection 2021 Sep. PMID: 34514194. PMCID: PMC8419128.
152. Vinson AJ, Kiberd BA, West K, **Mannon RB**, Foster B, Tennakore KK. Disparities in Access to Preemptive Repeat Kidney Transplant: Still Missing the Mark? *Kidney360* October 2021, 10.34067/KID.0003162021; DOI: <https://doi.org/10.34067/KID.0003162021>.
153. Tambur AR, Kosmoliaptis VM Claas FHJ, **Mannon RB**, Nickerson P, Naesens M. Significance of HLA-DQ in Kidney Transplantation-Time to Re-evaluate HLA matching priorities to improve transplant outcomes: An Expert Review and Recommendations. *Kidney Int*. 2021 Nov;100(5):1012-1022. doi: 10.1016/j.kint.2021.06.026. Epub 2021 Jul 8.
154. Madill-Thomsen KS, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Hidalgo LG, Myslak M, Viklicky O, Perkowska-Ptasinska A, Halloran PF, **Mannon R**, Serón D, Sellarés J, Akalin E, de Freitas D, Picton M, Weir M, Budde K, Heinbokel T. Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection. *Jnl Am Soc Neph* 2021; 32(11): 2743-2758; DOI: <https://doi.org/10.1681/ASN.2021040433>.
155. Vinson AJ, Agarwal G, Dai R, Anzalone AJ, Lee SB, French E, Olex A, Madhira V, **Mannon RB**. COVID-19 In Solid Organ Transplantation (SOT): Results of The National COVID Cohort Collaborative (N3C). *Transplant Direct*. 2021 Oct 6;7(11):e775. doi: 10.1097/TXD.0000000000001234. eCollection 2021 Nov. PMID: 34646938. PMCID: PMC8500600.
156. Andersen KM, Bates B, Rashidi ES, Olex AL, **Mannon RB**, Patel RC, Singh JA, Sun J, Auwaerter PG, Ng DK, Segal JB, Baribaldi BT, Mehta HB, Alexander GC. Use of Chronic Immunosuppressive Medicines and In-Hospital COVID-

- 19 Outcomes: A retrospective cohort study using the National COVID Cohort Collaborative (N3C). *Lancet Rheumatol.* 2022 Jan;4(1):e33-e41. PMID: 34806036. PMCID: PMC8592562.
157. Vinson AJ, Dai R, Agarwal G, Anzalone AJ, Lee SB, French E, Olex A, Madhira V, **Mannon RB**. Predictors of Major Adverse Renal or Cardiac Events in Solid Organ Transplant Recipients with COVID-19: A Cohort Study. *Am J Transplant.* 2022 Jan;22(1):245-259. doi: 10.1111/ajt.16865. Epub 2021 Nov 1. PMID: 34637599. PMCID: PMC8653020.
158. Sun J, Zheng Q, Madhira V, Vinson A, Singh JA, Olex AL, French E, Abraham AG, Mathew J, Safdar N, Pyarajan S, Agarwal G, Fitzgerald KC, Mowry E, Singh N, **Mannon RB**, Kirk GD, Patel R on behalf of the National COVID Cohort Collaborative (N3C) Consortium. Association Between Immune Dysfunction and Post-SARS-CoV-2 Vaccination Breakthrough Infections: Retrospective Cohort Study from a U.S. Nationally Sampled Database. *JAMA Intern Med.* 2022 Feb 1;182(2):153-162. doi: 10.1001/jamainternmed.2021.7024. PMID: 34962505. PMCID: PMC8500600.

Reviews

1. **Mannon RB**, Coffman TM. Immunologic mechanisms of transplant rejection. *Current Opinion in Nephrology and Hypertension* 1992; 1(2):230-5.
2. **Mannon RB**, Coffman TM. Gene targeting: applications in transplantation research. *Kidney Int* 1999; 56:18-27.
3. Hale DA, Swanson SJ, **Mannon RB**, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Kirk AD. Immunologic monitoring of the transplant recipient: challenges and approaches using antibody induction. *Transplantation Reviews* 2003, 17:S20-S25.
4. **Mannon RB**. Polyomavirus nephropathy: What have we learned? *Transplantation* 2004, 77(9) 1313-1318.
5. Dhanireddy KK, Xu H., **Mannon RB**, Hale DA, Kirk AD. The Clinical Application of Monoclonal Antibody Therapies in Renal Transplantation. *Expert Opinion in Emerging Drugs* 2004, 9(1): 23-37.
6. Elster EA, Hale D, **Mannon RB**, Cendales L, Swanson SJ, Kirk AD. The Road to Tolerance: Attempts at Renal Transplant Tolerance Induction in Non-Human Primate Studies and Clinical Trials. *Transplant Immunol* 2004, 13(2): 87-99.
7. Kirk AD, **Mannon RB**, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. *Transplant Int* 2005, 18(1): 2-14.
8. **Mannon RB**. Therapeutic targets of allograft fibrosis. *American Journal of Transplantation* 2006, 6:867-875.
9. **Mannon RB**, Kirk AD. Beyond Histology: Novel Tools to Diagnose Allograft Dysfunction. *Clinical Journal of the American Society of Nephrology* 2006, 1:358-366.
10. Girlanda R, **Mannon RB**, Kirk AD. Diagnostic Tools for the Monitoring of Kidney Transplant Recipients. *Seminars in Nephrology* 2007, 27:462-478.
11. Kowalski RJ, Zeevi A, **Mannon RB**, Britz JA, Carruth LM. Immunodiagnostics: Evaluation of Functional T-Cell Immunocompetence in Whole Blood Independent of Circulating Cell Numbers. *Journal of Immunotoxicology* 2007, 4:225-232.
12. Chandraker A, Mannon RB. Care of the kidney transplant recipient. *Clinical Journal of the American Society of Nephrology* 2008, 3 Suppl 2:S27-8.
13. Jevnikar AM, **Mannon RB**. Late Kidney Allograft Loss: What We Know About It and What We Can Do About It. *Clinical Journal of the American Society of Nephrology* 2008, 3 Suppl 2:S56-S67.
14. **Mannon RB**. Therapeutic Management of Post-Transplant Diabetes Mellitus. *Transplantation Reviews* 2008, 22:116-124.
15. Cravedi P, **Mannon RB**. Non-invasive methods to assess the risk of kidney transplant rejection. *Expert Review in Clinical Immunology* 2009;5: 535-546.
16. **Mannon RB**. Immune monitoring and biomarkers to predict chronic allograft dysfunction. *Kidney International* 2010, 78(Supplement 119); S59-S65.
17. Lo DJ, Weaver TA, Kleiner DE, **Mannon RB**, Jacobson LM, Becker BN, Swanson SJ, Hale DA, Kirk AD. Chemokines and their receptors in human renal allotransplantation. *Transplantation* 2011; 91:70-77.
18. **Mannon RB**. Macrophages: Contributors to Allograft Dysfunction, Repair or Innocent Bystanders? *Current Opinion in Organ Transplantation*, 2012, 17(1) 20-25.
19. Ong S, **Mannon RB**. Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine. *Transplantation Reviews* 2015 Apr;29(2):60-7. PMID: 25542607.
20. James A, **Mannon RB**. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? *Current Transplantation Reports*, 2015; 2(2):113-121.
21. **Mannon RB**. Delayed Graft Function: The AKI of Kidney Transplantation. *Nephron*, 2018; 140(2):94-98. PMID: 30007955. PMCID: PMC6167500.
22. **Mannon RB**. Transplantation: Acute kidney injury. *Nephron*, 2019; 143(3): 193-196. (DOI:10.1159/000500550).

PMID 31096218.

23. Cooper DKC, Hara H, Iwase H, Yamamoto T, Jagdale A, Kumar V, **Mannon R**, Hanaway M, Anderson D, Eckhoff D. Clinical Pig Kidney Xenotransplantation: How Close are We? *JASN* 2019, 31(1): 12-21, PMID 31792154.
24. Lentine KL, **Mannon RB**. Advancing American Kidney Health (AAKH) Executive Order: Promise and Caveats for Expanding Access to Kidney Transplantation. *Kidney360* 2020;1(6):557-560. doi:10.34067/KID.0001172020. PMID: 32587954 PMCID: PMC7316167.
25. Lentine KL, **Mannon RB**. APOL1 - Role in Donor Evaluation in Transplantation. *Curr Opin Nephrol Hypertens*. 2020 Nov;29(6):645-655. PMID: 33009133; PMC7741488.
26. Cravedi P, Schold JD, Safa K, Kates OS, Elfadawy N, **Mannon RB**, Shah MS, Hammond SP, Avery R, Fiella LV, Jowsey-Gregoire S, Akalin E, Camarind G, Alegre M-L, Azzi J. The COVID-19 Pandemic: A community approach. *Clin Transplant*. 2020 Nov;34(11):e14059. doi: 10.1111/ctr.14059. Epub 2020 Sep 28. PMID: 32762055. PMC7435543.
27. Vinson AJ, Chong AS, Clegg D, Falk C, Foster BJ, Halpin A, **Mannon RB**, Palmer BF, Oertelt-Prigione S, West LJ, Wong G, Sapir-Pishhadze R. Sex Matter: COVID-19 in Kidney Transplantation. *Kidney Int*. 2021; 99(3): 55-585. PMID 33412163. PMCID: PMC7783460.
28. Lentine KL, **Mannon RB**, Josephson MA. Practicing with Uncertainty: Kidney Transplantation during the COVID-19 Pandemic. *Am J Kidney Dis*. 2021 May;77(5):777-785. doi: 10.1053/j.ajkd.2020.12.003. Epub 2021 Jan 1. PMID: 33388404 PMCID: PMC7946342.
29. Langewisch E, **Mannon RB**. Chronic Allograft Injury. In press January 2021. *Clin J Am Soc Nephrol*. 2021 Apr 5:CJN.15590920. doi: 10.2215/CJN.15590920. Online ahead of print. PMID: 33820759. PMCID: PMC8729407.
30. Westphal S, **Mannon RB**. Emerging Biomarkers in Kidney Transplantation and Challenge of Clinical Implementation. *Curr Opin Organ Transplant* 2022; 27(1):15-21. PMID 34939960.

Manuscripts in Press

1. Matas A, Helgeson R, Fieberg A, Leduc R, Gaston R, Kasiske B, Rush D, Hunsicker L, Cosio F, Grande J, Cecka J, Connett J, **Mannon RB**. Risk Prediction for Delayed Allograft Function: Analysis of the Deterioration of Kidney Allograft Function (DeKAF) Study Data. *Transplantation*. 2021 Feb 23. doi: 10.1097/TP.0000000000003718. Online ahead of print. PMID: 33675321 PMCID: PMC8380757.
2. Axelrod DA, Ince D, Harhay MN, **Mannon RB**, Alhamad T, Cooper M, Josephson MA, Caliskan Y, Sharfuddin A, Kumar V, Guenette A, Schnitzler MA, Ainapurapu S, Lentine KL. Operational Challenges in the COVID Era: Asymptomatic Infections and Vaccination Timing. *Clin Transplant*. 2021 Jul 23. doi: 10.1111/ctr.14437. Online ahead of print. PMID: 34297878. PPMCID: PMC8420523.
3. **Mannon RB**. In Memoriam: Barbara T Murphy. *Clin Transplant*. 2021 Aug 3:e14446. doi: 10.1111/ctr.14446. Online ahead of print. PMID: 34342901.
4. Cooper TE, Au EH, Chung EYM, Tunnicliffe DJ, Craig JC, Gesualdo L, Howell M, Mannon P, **Mannon R**, Strippoli GFM, Teixeira-Pinto A, Tong A, Wong G. Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease. *Cochrane Database of Systematic Reviews*, in press 2022. DOI: 10.1002/14651858.CD014786.
5. Raza SS, Agarwal G, Anderson D, Deierhoi M, Fatima H, Hanaway M, Locke J, MacLennan P, Orandi B, Young C, **Mannon RB**, Seifert ME. Abnormal Time-Zero Histology is Predictive of Kidney Transplant Outcomes. *Clinical Transplantation* Jan 20,2022.
6. Jayanti S, Beruni NA, Chui K, Deng C, Liang A, Chong A, Craig JC, Foster B, Howell M, Kim S, Sapir-Pichadze, **Mannon R**, Scholes-Robertson N, Strauss A, Tong A, West L, Cooper TE, Wong G.. Sex and gender as predictors for allograft and patient relevant outcomes after kidney transplantation (Protocol). *Cochrane Database of Systematic Reviews* TBD, Issue TBD. Art. No.: CD014966. DOI: 10.1002/14651858.CD014966.
7. Vinson AJ, Singh S, Chadban S, Cherney D, Gill JS, Helgeson E, Herzog CA, Jardine M, Jha V, **Mannon RB**, Michos ED, Mottle AK, Newby LK, Sawinski D, Sharif A, Sridhar VS, Tuttle KR, Vock DM, Matas A. *Jnl Am Soc Nephrol* Feb 4 2022. Premature Death in Kidney Transplant Recipients: The Time for Trials is Now.
8. Singh N, Li R, Alhamad T, Schnitzler M, **Mannon RB**, Doshi MD, Woodside K, Hippen BE, Cooper M, Snyder J, Axelrod DA, Lentine KL. Exacerbation of Racial Disparities in Living Donor Kidney Transplantation During the COVID-19 Pandemic. *Kidney360* in press March 2022.
9. Lentine KL, Fleetwood VA, Caliskan Y, Randall H, Wellen JR, Lichtenberger M, Dedert C, Rothweiler R, Marklin G, Brockmeier C, Schnitzler MA, Husain Sa, Mohan S, Kasiske BL, Cooper M, **Mannon RB**, Axelrod DA. Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision Making: A Survey of U.S. Transplant Centers". *Kidney International Reports* March 2022 in press.

10. Han M, Wong G, Kute VB, Nakagawa Y, Wang H-H, Arakama MH, Jeong JC, Cho YY, Twin KT, Chapman J, Sapir-Pichhadze R, **Mannon RB**, Ahn C, Kim YH. Gender disparity in Asian-Pacific countries: An analysis of the ASTREG-WIT-KT Registry. Transplantation May 2022.

Manuscripts submitted but not yet accepted

1. Oetting, WS, Guan W, Dorr CR, **Mannon RB**, Matas AJ, Jacobson PA, Israni A, and DeKAF Genomics/GEN03 Investigators. *LIMS1* variant rs893403 does not associate as a risk factor for acute rejection in kidney allograft recipients in the DeKAF Genomics or GEN03 cohorts.
2. Dorr C, Guan W, Van Settern J, Loza B-L, De Borst M, Bakker S, Van der Most P, Snieder H, Phelan P, Conlon P, Gilbert E, Birdwell K, Reindl-Schwaighofer R, Heinzel A, Oberbauer R, Cavalleri G, Muthusamy A, Onyeaghala G, Remmel R, Kwok P-Y, Eikmans M, Yang J, Claas F, Viklicky O, Asselbergs F, Lord G, **Mannon R**, Matas A, Schladt D, Wu B, Oetting W, Jacobson P, Keating B, Israni A. Genome-Wide Association Study Meta-Analysis of Kidney Allograft Rejection.
3. Obayemi J, Keating B, Callans L, Lentine KL, Schnitzler MA, Caliskan Y, Xiao H, Dharnidharka VR, **Mannon RB**, Axelrod DA. Impact of CYP3A5 Status on the Clinical and Financial Outcomes of Kidney Transplant. Transplantation Direct.
4. Dong Jianghu, **Mannon RB**, Zhang P. A Nonparametric Method to Estimate the Nonlinear Effect of Aggregate Exposures in Case-Control Studies. Biometrical Journal.
5. Nickerson PW, Bohmig GA, Chadban S, Kumar D, **Mannon RB**, van Gelder T, Lee JC, Adler S, Cong E, Djamali A. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
6. Reininger KA, Onyeaghala G, Anderson-Haag T, Wu B, Guan W, Dorr C, Remmel R, **Mannon R**, Matas A, Oetting W, Israni A, Stahler P, Jacobson PA. Higher number of tacrolimus dose adjustments in kidney transplant recipients who have an CYP3A5 extensive and intermediate metabolism phenotype.
7. Vinson AJ, Anzalone AJ, Sun J, Dai R, Agarwal G, Lee SB, French E, Olex A, **Mannon, RB**. Consequences of Breakthrough COVID-19 Infection in Solid Organ Transplant Recipients Relative to Non-Immunosuppressed Controls.
8. Sun J, Zheng Q, Anzalone AJ, Abraham AG, Olex AL, Zhang Y, Mathew J, Safdar N, Haendel MA, Segev D, Islam JY, Singh JA, **Mannon RB**, Chute CG, Patel RC, Kirk GD for the National COVID Cohort Collaborative (N3C). COVID-19 Booster Vaccine Effectiveness in People With and Without Immune Dysfunction Over time.

Manuscripts in preparation

Other Publications (letters to the author, book reviews, etc.)

Editorials

1. **Mannon, R.B.** Leflunomide Therapy in Kidney Transplantation: Ready for Prime Time? Clinical Journal of the American Society of Nephrology 2008, 3:652-653.
2. Cravedi P, **Mannon RB**, Remuzzi G. Lymphocyte depletion for kidney transplantation: Back to the past? Nature Clinical Practice Nephrology 2008, 4:534-535.
3. Cravedi P, **Mannon RB**, Ruggenti P, Remuzzi A, Remuzzi G. Islet transplantation: Need for a time-out? Nature Clinical Practice Nephrology 2008, 4:660-1.
4. **Mannon RB**, Fairchild R. Allograft fibrosis: Unmasking the players at the dance. American Journal of Transplantation, 2010; 10: 201-202.
5. Alloway RR, Schroeder T, Vincenti F, **Mannon RB**. "A Call to Action; Reviving the Pipeline of Therapeutic Agent and Device Innovation in Transplantation". Submitted May 13, 2013. https://www.myast.org/sites/default/files/pdfs/fda_moucalltoaction_final_5_13_13.pdf.
6. **Mannon RB**. Necroptosis and Apoptosis in Solid Organ Transplantation: A Missing Link to Immune Activation? Am Journal of Transplantation 2013, 13(11): 2785-6. PMID 24103049.
7. **Mannon RB**. Personalized medicine in kidney transplantation: In our lifetime? Clinical Journal of the American Society of Nephrology Self-Assessment Program (NephSAP), 2015; 14 (5), 368-374.
8. **Mannon RB**. The Banff Schema of Allograft Pathology: Lost in Translation? American Journal of Transplantation, 2019 Jan;19(1):9-10. doi: 10.1111/ajt.15033. Epub 2018 Aug 13. PMID: 30040194.
9. **Mannon, RB**. Is it Time for Operation Warp Speed in Transplant Research? Transplantation Direct 2020 Oct 20;6(11):e619. doi: 10.1097/TXD.0000000000001073. eCollection 2020 Nov. PMID: 33134495 PMCID: PMC7581020.

10. Helanterä I, **Mannon RB**, Mengel M. Industry partnerships in transplantation: How should AJT manage the inevitable conflict of interest? Letter to the Editor, *Am J Transplant*. 2021 May;21(5):1988-1989. doi: 10.1111/ajt.16447. Epub 2021 Jan 2. PMID: 33315303.
11. Steiner R, **Mannon RB**. A Glossary for Patient Care and Scientific Dialogue from KDIGO. *Am J Transplant*. 2021 Feb;21(2):458-459. doi: 10.1111/ajt.16226. Epub 2020 Sep 4. PMID: 32715589
12. Mengel M, **Mannon, RB**. Banff and ABMR: Are we going in the right direction? *Am J Transplant*. 2021 Jul;21(7):2321-2322. doi: 10.1111/ajt.16546. Epub 2021 Mar 5. PMID: 33621422.
13. Ford ML, **Mannon RB**. Time for Increased Awareness of Sex as a Biological Variable in Transplantation. *Am J Transplant*. 2021 Oct;21(10):3215-3216. doi: 10.1111/ajt.16733. Epub 2021 Jul 12. PMID: 34174152 PMID: 34174152.
14. Lalji R, **Mannon RB**. From the cradle to the grave - the life cycle of gender disparities in kidney care. *Kidney Int Rep*. 2022 Jan 24;7(3):363-365. PMID: 35257048. PMCID: PMC8897495. <https://doi.org/10.1016/j.ekir.2022.01.1051>.
15. Lentine KL, **Mannon RB**, Mandelbrot D. Understanding and Overcoming Financial Risks for Living Organ Donors. Editorial, *Am J Kidney Dis*. 2022 Feb;79(2):159-161. PMID: 34872794. PMCID: doi: 10.1053/j.ajkd.2021.09.003.
16. Chadran S, **Mannon RB**. T-cell mediated rejection in Kidney Transplant: The End(point) is also the Beginning. *Am J Transplant* 2022; 22 (3): 683-684. PMID: 35073440.

Letters to the Editor

1. Mrug M, Zhou J, **Mannon RB**. C3 Polymorphisms and Allograft Outcome in Renal Transplantation. Letter to the Editor *New England Journal of Medicine* 2009; 360:2477-2478.
2. Mehta S, Chang JH, Alhamad T, Bromberg JS, Hiller DJ, Drskovic M, Yee JP, **Mannon, RB**. Repeat Kidney Transplant Recipients with Active Rejection Have Elevated Donor-Derived Cell-Free DNA. *Am J Transplant*. 2019 May;19(5):1597-1598. doi: 10.1111/ajt.15192. Epub 2018 Dec 10. No abstract available. PMID: 30468563
3. Nellore A, **Mannon RB**, Limaye AP. Letter to the Editor. *Clin Infect Dis* 2019 Jul 25. pii: ciz495. doi: 10.1093/cid/ciz495. [Epub ahead of print] PMID: 31340381.
4. Matas AM, **Mannon RB**, Rush D, Helgeson E. Novel Phenotypes for Acute Kidney Transplant Rejection Using Semi-Supervised Clustering. *J Am Soc Nephrol*. 2021 Sep;32(9):2387-2388. doi: 10.1681/ASN.2021040572. Epub 2021 Aug 16. PMID: 34403355.
5. Vinson A, Chong A, Clegg D, Falk C, Foster B, Halpin A, **Mannon RB**, Oertelt-Prigione S, Palmer B, Sapir-Pichhadze R, West L, Wong G. Incorporation of Sex and Gender Guidelines into Transplantation Literature. Letter to the Editor. *Transplantation*. 2021 Nov 1;105(11):e261-e262. doi: 10.1097/TP.0000000000003967. PMID: 34593746.

Other

1. **Mannon RB**. Contributor, Transplant Therapeutic Consortium Food and Drug Administration Letter of Intent for Biomarker Qualification, June 2020.

BOOKS:

(Numbered, in chronological order)

Books and Book Chapters

1. Thuillier R, **Mannon RB**. The immunology of chronic allograft injury in Chronic Allograft Failure: Natural History, Pathogenesis, Diagnosis and Management. N.L. Ahsan Ed. Landes Biosciences. 2007, <http://eurekah.com/chapter/3237>.
2. **Mannon RB**. IgA Nephropathy and Kidney Transplantation. In: Immunology: Clinical Case Studies and Disease Pathophysiology. Strober and Gottesman, eds. Wiley-Blackwell, Hoboken, NJ, 2009, 255-269.
3. **Mannon RB**. Post-Transplant Monitoring and Outcomes. In: National Kidney Foundation Primer of Kidney Disease. 5th Edition. A. Cheung and A. Greenberg, Eds. 2009, 534-542.
4. Prendergast M, **Mannon RB**. Kidney Transplantation: A Guide of the Care of Transplant Recipients: Chapter 18: Malignancies Before and After Transplantation. D. McKay, Ed. Springer-Science, New York, NY, 2010.
5. Mehta S, **Mannon RB**. Early Graft Dysfunction. In: Clinical Decision Support System on Nephrology and Hypertension. Linus, Tittle, Himmelfarb eds. In press, 2013.
6. **Mannon RB**. Organ Specific Features. In AST Handbook of Transplant Immunology. First Edition. X Li and A Jevnikar Editors. In Press 2013.
7. Mehta S and **Mannon RB**. Chronic transplant dysfunction. In A companion to specialist surgical practice: Transplantation, 5th edition. John Forsythe editor. 2013.
8. Kamal AI and **Mannon RB**. Malignancies after transplantation and post-transplant lymphoproliferative disorder. In Kidney Transplantation: A Practical Guide to Medical Management. M Weir and E Lerma, Editors. Springer-Science New York, 2013.

9. Gunaratnam L, Jevnikar AM, **Mannon, RB**. Experimental transplantation: small animal models. In Textbook of Organ Transplantation. First Edition. AD Kirk, SJ Knechtle, CP Larsen, JC Madsen, TC Pearson, Webber SA, Editors. Wiley Publishers 2014. Chapter 14; 158-184. <https://doi.org/10.1002/9781118873434.ch14>.
10. Seifert ME, **Mannon RB**. Modernization of Chronic Allograft Injury Research: Better Biomarkers, Better Studies, Better Outcomes. Clinical Transplantation 2015; 31: 211-235.
11. Mannon EC, Wood K, **Mannon RB**. Chapter 90: Solid organ transplantation: Rejection, immunosuppression, tolerance. In: Clinical Immunology, Rich R eds, 6th edition, Elsevier, Amsterdam, Netherlands. July 2020.

Published abstracts

(Numbered, in chronological order)

Poster Exhibits (since 2010)

1. Srivastava M, Torosyan Y, Huang W, Eidelman O, Jozwik C, Pollard H, **Mannon R**. GenePattern and Ingenuity Pathway Analysis Based Selection of Protein Microarray-derived Serum Biomarkers for Acute and Chronic Kidney Allograft Rejection. (Poster presentation at the US HUPO Annual Meeting 2010, Denver CO).
2. Chen J, Zmijewska A, **Mannon RB**. The complex miRNA regulation of allograft fibrosis in late kidney allograft failure. (Poster presentation at the American Transplant Congress 2010, San Diego, CA).
3. Khamash H, Gaston RS, **Mannon RB**. Outcomes Of Low Immunologic Risk Kidney Transplant Recipients (KTRs) Receiving Depletional Induction. (Poster presentation at the American Transplant Congress 2010, San Diego, CA).
4. Leduc R, Connett J, Cecka JM, Cosio F, Grande J, Gourishankar S, Halloran P, Hunsicker L, Kasiske B, Rush D, **Mannon RB**, Matas A. Quantitating risk of late allograft failure (LGF): A novel score derived from analysis of kidney histology at the time of initial graft dysfunction. (Poster presentation at the American Transplant Congress 2010, San Diego, CA).
5. Prendergast M, Curtis JC, Deierhoi MH, Baddley JW, **Mannon RB**. Barriers to Renal Transplantation for HIV Positive Patients with Chronic Kidney Disease in the South Eastern United States. (Poster presentation at the American Transplant Congress 2010, San Diego, CA).
6. Mehta S, Gaston RS, Julian BA, **Mannon RB**, Kumar V. Depletional versus non-depletional induction therapy at time of kidney transplantation in patients on immunosuppression for a functional non-renal solid organ allograft. (Poster presentation at the American Transplant Congress 2011, Philadelphia, PA).
7. Kumar V, Hauptfeld-Dolejssek V, Senkbeil R, **Mannon R**, Gaston RS, Bynon S, Dubay DA. Outcomes in simultaneous liver kidney transplants in the setting of a positive crossmatch. (Poster presentation at the American Transplant Congress 2011, Philadelphia, PA).
8. Jacobson P, Schladt D, Oetting W, Matas A, Kim M, Leduc R, Guan W, **Mannon R**, Lamba V, Israni A. Donor and recipient single nucleotide polymorphisms (SNPs) and mycophenolate pharmacokinetics: results from a multicenter consortium. (Poster presentation at the American Transplant Congress 2011, Philadelphia, PA).
9. Rush D, Somorjai R, Dolenko B, Cecka M, Cosio F, Gaston R, Gourishanker S, Grande J, Halloran P, Hunsicker L, Kasiske B, **Mannon R**, Leduc R, Connett J, Matas A. Validation of Urine Magnetic Resonance Spectra (UMRS) for the Diagnosis of Renal Allograft Pathology: Results from the DeKAF Study. (Poster Presentation at the American Transplant Congress 2012, Boston, MA).
10. Chen J, Sanders D, Zmijewska A, **Mannon RB**. Vitronectin/Integrin αV : A novel pathway mediating kidney allograft failure. (Poster presentation at the American Transplant Congress 2012, Boston MA).
11. Weir M, Vincenti V, Von Visger V, Kopyt N, **Mannon RB**, Tseng S, Goodman W, Wolf M. Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients: A Prospective Cohort Study. (Poster Presentation at the American Transplant Congress 2012, Boston MA).
12. Aggarwal H, Kumar N, Mehta S, **Mannon R**, Heo J, Iskandrian A, Hage F. Heart rate response to adenosine is an independent predictor of long-term mortality in end stage renal disease. (Poster presentation at the American Heart Association Meeting 2012, Los Angeles, CA).
13. Kumar N, Aggarwal H, Mehta S, **Mannon R**, Heo J, Iskandrian A, Hage F. Risk Assessment in End-Stage Renal Disease with Myocardial Perfusion Imaging Beyond Left Ventricular Perfusion and Function: The Role of Dyssynchrony. (Poster presentation at the 62nd Annual Scientific Session of the American College of Cardiology 2013, San Francisco, CA).
14. Himanshu Aggarwal, Shikha Mehta, **Roslyn Mannon**, Jaekyeong Heo, Ami E Iskandrian, Fadi G Hage, Heart Rate Response to Adenosine is an Independent Predictor of Long-term Mortality in End Stage Renal Disease. (Presented at the AHA 2012 meeting).
15. Rush D, Leduc R, Connett F, Cosio F, Gaston R, **Mannon R**, Hunsicker L, Gourishankar S, Halloran P, Cecka M, Grande J, Kasiske B, Matas A. DeKAF pathology clusters: follow up of 5 years. (Accepted for poster discussion at the American Transplant Congress 2013, Seattle, WA).

16. Suessmuth Y, Stempora L, Johnson B, Cheeseman J, Morrison Y, Bridges N, Ikle D, Tomlanovich S, Stock P, **Mannon R**, Newell K, Larsen C, Mehta A. Comparison of baseline and day 28 post transplant renal allograft samples from the CTOT-10 belatacept study. (Poster presentation at the American Transplant Congress 2013, Seattle, WA).
17. Crosland W, Aggarwal H, Mehta S, **Mannon R**, Heo J, Iskandrian AE, Hage FG. The effect of kidney transplantation on left ventricular systolic function and mechanical dyssynchrony by gated myocardial perfusion imaging. *J Invest Med* 2014;62:386.
18. Zmijewska AA, Chen J, Zmijewski JW, **Mannon RB**. High-mobility group box 1: A novel mediator of late kidney allograft injury. (Poster presentation at the World Transplant Congress 2014, San Francisco, CA).
19. Diskin D, Reed R, Locke J, Williams T, **Mannon R**, Gaston R, Kumar V. To treat or not to treat : Late antibody mediated rejection (AbMR) in transplant recipients with intravenous immunoglobulin (IVIg) and corticosteroids. (Poster of Distinction, World Transplant Congress 2014, San Francisco, CA).
20. **Mannon RB**, Reed R, Locke J. Kidney transplantation in Nephropathic cystinosis: Outcomes in the 21st century. (Poster of Distinction, World Transplant Congress 2014, San Francisco, CA).
21. Young C, Reed RD, Mannon E, **Mannon RB**, Locke JE. Mitigation of racial disparities after simultaneous pancreas and kidney transplantation. (Poster of Distinction, World Transplant Congress 2014, San Francisco, CA).
22. Donnelly JP, Wang HE, Locke J, **Mannon RB**, Baddley JW. Healthcare Facility-Associated Clostridium difficile Infection in Solid Organ Transplant Recipients. (Poster of Distinction, World Transplant Congress 2014, San Francisco, CA).
23. Sanghavi k, Brundate R, Miller M, Schaldt D, Israni AK, Guan W, Oetting WS, Mannon R, Remmel RP, Matas A, Jacobson PA. Genotype guided tacrolimus dosing equation for African American kidney transplant recipients. (Poster Presentation, American Transplant congress 2015, Philadelphia, PA).
24. J. Chen, A. Zmijewska, **R. Mannon**. Renal Fibroblast Activation and Survival by Anti-MHC Class I Antibody: The Role of mTOR Signaling Pathway. (Poster Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
25. M. Yanik, **R. Mannon**, M. Seifert. Unexpected Early Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients. (Poster Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
26. A. Zmijewska, J. Chen, J. Zmijewski, **R. Mannon**. Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation. (Poster Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
27. K. Keslar, A. Zmijewska, J. Andringa, K. Newell, **R. Mannon**, P. Heeger, R. Fairchild. NanoString Detection of Gene Signatures in Urine During Acute Cellular Rejection of Kidney Grafts. (Poster Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
28. D. Berglund, D. Schladt, K. Sanghavi, W. Guan, B. Wu, C. Dorr, R. Remmel, R. Mannon, A. Matas, W. Oetting, A. Israni, P. Jacobson, DeKAF Genomics Investigators. High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients. (Oral Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
29. W. Oetting, D. Schladt, W. Guan, R. Remmel, C. Dorr, K. Sanghavi, A. Matas, **R. Mannon**, A. Israni, P. Jacobson, For DeKAF Genomics, GEN-03 Investigators. Differences in Tacrolimus Troughs and Doses Between Caucasians and African Americans with Two CYP3A5 Loss-of-Function Alleles: Looking Beyond CYP3A5 Expression. (Poster Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
30. C. Dorr, A. Hart, D. Schladt, A. Muthusamy, **R. Mannon**, W. Oetting, A. Matas, P. Jacobson, A. Israni. Clinical Outcomes of Kidney Allograft Recipients with Apolipoprotein L1 (APOL1) Risk Alleles from Living Kidney Donors. (Poster Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
31. Seifert ME, Yanik MV, Hauptfed-Dolejssek V, **Mannon RB**. Early Subclinical Inflammation and Humoral Alloimmune Responses in Pediatric Kidney Transplantation. (Poster presentation, American Transplant Congress 2017, Chicago, IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
32. Seibert SR, Schladt CP, Wu B, Guan A, Dorr C, Berglund D, Remmel RP, Matas AJ, **Mannon RB**, Israni AK, Oetting WS, Jacobson PA. Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients. (Poster presentation, American Transplant Congress 2017, Chicago, IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
33. Margraf D, Brundage R, Schladt D, Guan W, Baolin W, Remmel RP, Dorr C, Berglund D, **Mannon RB**, Matas AJ, Oetting WS, Israni AK, Jacobson PA. Personalized tacrolimus (TAC) dosing using genetic variants in Caucasian kidney transplant (Tx) recipients. (Poster presentation, American Transplant Congress 2017, Chicago, IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
34. K. Keslar, A. Zmijewska, J. Chen, K. Newell, P. Heeger, **R. Mannon**, R. Fairchild. Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts. (Poster presentation, American Transplant Congress 2017, Chicago, IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).

35. P. Cravedi, I. Gandolfini, C. Donadei, R. Fairchild, K. Newell, **R. Mannon**, P. Heeger, CTOT16 Consortium. Pre-Transplant Panel Reactive T Cells (PRT) with IL-15 as a Risk-Stratifier of Acute Rejection in Kidney Transplant Patients on Belatacept Therapy. (Poster presentation, American Transplant Congress 2017, Chicago, IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
36. P. Bryant, P. Pappas, C. Huisinigh, **R. Mannon**, J. Locke, K. Wille, D. Eckhoff, J. Tallaj, J. Baddley. Outcomes Following Reduction of Immunosuppression in Solid Organ Transplant Recipients with Cryptococcosis. (Poster presentation, American Transplant Congress 2017, Chicago, IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
37. Zmijewska AA, Murphy J, Chen J, Zmijewski JW, **Mannon RB**. Assessing Necroptosis in Brain Dead Kidney Donors: Implications for Predicting Recipient Outcomes. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
38. Bernard M, Agarwal G, Fatima H, Julian BA, Kew C, Kumar V, Mehta S, Ong S, Patel A, Towns G, Seifert ME, **Mannon RB**. Subclinical Borderline Rejection: More Than Meets the Eye? Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
39. Seifert ME, Perry PR, Romp R, **Mannon RB**, Pollock JS. Early Life Stress Exposure and Cardio-Renal Outcomes in Pediatric Kidney Transplantation. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
40. Seifert ME, Malone A, Booharker L, Gaut J, Jain S, Brennan D, **Mannon RB**. Circulating Wnt Pathway Factors Are Non-Invasive Biomarkers of Transplant Vascular Injury. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
41. Reed RD, Massie AB, Sawinski D, MacLennan PA, Shelton AB, Musian MN, McWilliams DM, Kumar V, **Mannon RB**, Gaston R, Segev DL, Lewis DE, Locke JE. Obesity is Associated with Increased Risk of Mortality among Living Kidney Donors.
42. Donnelly J, MacLennan P, **Mannon R**, Saran R, Baddley J, Wang HG, McGwin G, Muntner P. Association of Tacrolimus Adherence and Discontinuation with Sepsis Risk Among Kidney Transplant Recipients. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
43. Donnelly J, MacLennan P, **Mannon R**, Saran R, Baddley J, Wang H, McGwin G, Muntner P. Association of Immunosuppressive Therapy Regimen with Sepsis Outcomes among Kidney Transplant Recipients. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
44. Dorr Dr, Wu B, Remmel P, Muthusamy A, Schladt DP, Abrahante JE, Guan W, **Mannon RB**, Matas AJ, Oetting WS, Jacobson PA, Israni AK. Identification of Novel Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant Recipients Using Next Generation Sequencing. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
45. Jacobsons P, Schladt D, Weihau G, Van Setten J, Remmel R, Wu B, Dorr C, Keating B, Ikle D, **Mannon R**, Matas A, Israni A, Oetting W. Validation of Genetic Variants Identified in GWAS for Tacrolimus Troughs. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
46. Mehta S, Chang J, Hailey T, Hiller D, Grskovic M, Yee JP, **Mannon R**. Repeat Kidney Transplant Patients with Active Rejection Have Elevated Donor-Derived Cell-Free DNA. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
47. McCarty TP, Baddley JW, Locke JE, **Mannon RB**, Eckoff DE, Rusanov V, Moser AS, Pappas PG. T2Candida for Diagnosis of Candidemia in Solid Organ Transplant Recipients. Poster presentation at the 2018 American Transplant Congress, Seattle, WA.
48. Jacobson PA, Schladt DP, Oetting WS, Baolin W, Guan W, Dorr CR, Remmel RP, **Mannon RB**, Ikle DN, Matas AJ, Israni AK. Tacrolimus troughs and doses in African American, Asian, Caucasian and Hispanic/Native American Kidney Transplant Recipients. Poster presentation at American Society of Nephrology Kidney Week 2018, San Diego, CA, October 2018.
49. Oliver MB, Chen J, Zmijewska A, **Mannon RB**. Activation of renal fibroblasts by anti-major histocompatibility complex antibody: a missing link in allograft fibrosis. Poster presentation, American Transplant Congress, Boston, MA, June 2019.
50. Ang A, Zmijewska A, Stevens TM, Murphy J, **Mannon RB**. Innate immunity in brain dead donors: implications of necroptosis in kidney allograft outcomes. Poster presentation, American Transplant Congress, Boston, MA, June 2019.
51. Kasik EP, Seifert ME, Bernard M, Agarwal G, Fatima H, Gaston R, Julian B, Kew C, Kumar V, Mehta S, Ong S, Rosenblum F, Towns G, **Mannon RB**. Effect of race and antibody-mediated injury on outcomes after early subclinical inflammation. Poster presentation, American Transplant Congress, Boston, MA, June 2019.
52. Ang A, Schieve C, Rose S, Kew C, First MR, **Mannon RB**. Avoiding Surveillance Biopsy: How? When? Now! Poster presentation at the American Transplant Congress (Virtual), June 2020.
53. Al-Kofahi1 M, Oetting W, Israni A, Schladt D, Guan W, Wu B, Dorr C, Remel R, **Mannon R**, Pankratz N, Matas A, Jacobson P. Precision Dosing For Tacrolimus Using Genotypes and Clinical Factors. Poster Presentation at the American Transplant Congress (Virtual). June 2020.

54. Machado A, Agarwal G, Ahmed F, Julian B, **Mannon R**, Mehta S, Kumar V, Ong S, Thaduri S, Towns G, Kew C. Immunosurveillance with Donor Derived Cellular Free DNA Assay Plus Donor Specific Antibody, an Alternative to Renal Allograft Biopsy. Poster Presentation at the American Transplant Congress (Virtual). June 2020.
55. Oetting WS, Weihua G, Dorr CR, **Mannon RB**, Matas AJ, Jacobson PA, Israni AK. Attempted Validation of Lims1 Variant Rs893403 with Acute Rejection Risk. Poster Presentation at the American Transplant Congress (Virtual). June 2020.
56. Keslar KS, Margeta D, Feiedewald JJ, Abecassis M, **Mannon RB**, Heeger PS, Fairchild RL. Noninvasive Detection of Subclinical Rejection in Urine RNA. Poster Presentation at the American Transplant Congress (Virtual). June 2020.
57. Vinson AJ, Agarwal G, Dai R, French E, Lee S, Olex A, Anzalone A, Madhira V, **Mannon RB**. COVID-19 in Solid Organ Transplantation (SOT): Results of the National COVID Cohort Collaborative (N3C). Poster Presentation at the Cutting Edge of Transplantation 2021 Virtual Meeting, February 2021. Winner of young faculty award.
58. Nickerson P, Bohmig GA, Chadban S, Kumar D, **Mannon RB**, Van Gelder T, Adler S, Chong E, Djamali A. Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design. Poster Presentation at the American Transplant Congress, June 5–9, 2021 (virtual meeting).
59. M. N. Harhay MN, Klassen A, Zaidi H, Mittelman M, Bertha R, **Mannon R**, Lentine K. Living Organ Donor Perspectives on Covid-19 Vaccines. Poster Presentation at the American Transplant Congress, June 5–9, 2021 (virtual meeting).
60. R. Cao R, Arthur V, Chen J, Keating B, Dorr C, Schladt D, Onyeaghalala G, **Mannon RB**, Matas A, Remmel R, Pankratz N, Wu B, Oetting W, Jacobson P, Israni A, Guan W. Association Between Donor-Recipient Genetic Matching and Acute Rejection in Kidney Transplantation. Poster Presentation at the American Transplant Congress, June 5–9, 2021 (virtual meeting).
61. Lentine KL, Jones C, Cheungpasitporn W, Rothweiler R, Xiao H, Marklin G, Ortigosa-Goggins M, Lindsay KK, Schnitzler MA, Cooper M, **Mannon RB**. Next of Kin Authorization for Research in Deceased Donor Organ Transplantation Experience at one Organ Procurement Organization and Inferences for Practice Improvement. Poster Presentation at the American Transplant Congress, June 5–9, 2021 (virtual meeting).
62. Sun J, Zheng Q, Anzalone AJ, Abraham AG, Mathew J, Safdar N, Islam JY, Olex AL, **Mannon RB**, Chut CG, Patel R, Kirk GD. COVID-19 Booster Vaccine Effectiveness in People with and Without Immune Dysfunction. CROI 2022 virtual meeting.

Oral Presentations (since 2010)

(Numbered, in chronological order)

1. Chen J, Zmijewska A, **Mannon RB**. miR21 Upregulation May Contribute to the Fibrosis in Cyclosporine (CsA) Nephrotoxicity. (Oral presentation at the American Transplant Congress 2010, San Diego, CA).
2. Khamash H, Gaston RS, **Mannon RB**. The Protective Effect of Renin-Angiotensin System (RAS) Blockade in the Development of New Onset Diabetes After Transplantation (NODAT). (Oral presentation at the American Transplant Congress 2010, San Diego, CA).
3. **Mannon RB**, Matas AJ, Leduc R, Cecka JM, Cosio F, Gaston R, Gourishankar S, Halloran P, Hunsicker L, Kasiske B, Rush D, Grande J. Inflammation in Areas of Tubular Atrophy (iatr) Predicts Kidney Allograft Failure. (Oral presentation at the XXIII International Congress of the Transplantation Society 2010, Vancouver, British Columbia, CA).
4. Israni A, Schladt D, Leduc R, Lamba V, Guan W, Jacobson P, **Mannon R**, Oetting W, Matas A. Single nucleotide polymorphisms associated with severity of interstitial fibrosis/tubular atrophy (IF/TA) on kidney allograft biopsies. (Oral presentation at the American Transplant Congress 2011, Philadelphia, PA).
5. Israni A, Schladt D, Leduc R, Lamba V, Guan W, Jacobson P, **Mannon R**, Matas A, Oetting W. Inflammation in the setting of allograft dysfunction after three months post-kidney transplant: phenotype and genotype correlation. (Oral presentation at the American Transplant Congress 2011, Philadelphia, PA).
6. Chen J, Zmijewska A, **Mannon RB**. MicroRNA21: A new target to ameliorate cyclosporine nephrotoxicity. (Plenary oral session presentation, American Transplant Congress 2011, Philadelphia, PA).
7. Vincenti F, Weir M, Von Visger J, Kopyt N, **Mannon RB**, Tseng S, Goodman W, Wolf M. A prospective cohort study of persistent hyperparathyroidism in kidney transplant recipients. (Oral presentation at the XXIV International Congress of the Transplantation Society 2012, Berlin, Germany).
8. Locke J, James N, Mehta S, Pappas P, **Mannon R**, Desai N, Montgomery R, Segev D. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. (Oral presentation, American Transplant Congress 2013, Seattle, WA).
9. Gaston R, Leduc R, Cosio F, Gourishankar S, Grande J, Hunsicker L, Kasiske B, **Mannon R**, Matas A, Rush D, Cecka M. Antibody-mediated injury is the major cause of late allograft failure. (Oral presentation, American Transplant Congress 2013, Seattle, WA).

10. Newell K, **Mannon R**, Mehta A, Tomlanovich S, Morrison Y, Ikle D, Goodman J, Mehta S, Bridges N, Stock P, Larsen C. Long-term calcineurin inhibitor (CNI) and corticosteroid (CS) avoidance using Belatacept: The CTOT-10 experience. (Oral presentation, American Transplant Congress 2013, Seattle, WA).
11. Chen J, Antipenko A, Deierhoi A, Locke J, **Mannon RB**. Brain death is associated with loss of TLR signaling and upregulation of proinflammatory proteins. (Oral presentation, World Transplant Congress 2014, San Francisco, CA).
12. Gordon EJ, Ortiz K, Vera K, Martinez S, Sohn MW, Chang CH, McNatt G, Beauvais N, **Mannon R**, Ison MG. A decision aid for kidney transplant candidates about increased risk donor (IRD) kidneys: A randomized controlled trial of increased knowledge. (Oral presentation, World Transplant Congress 2014, San Francisco, CA).
13. Zmijewska AA, Chen J, Thuillier R, Zmijewski JW, **Mannon RB**. Cyclosporine Nephrotoxicity is Associated with Diminished Expression of Heat Shock Protein 27 (HSP27) and Loss of Claudin-2-Dependent Intercellular Adhesion. (Oral presentation, American Transplant Congress 2015, Philadelphia PA).
14. Chen J, Zmijewska A, **Mannon RB**. Chen J, Antipenko S, Zmijewska A, Deierhoi R, MacLennan P, Locke J, **Mannon RB**. Enhanced Production of Macrophage Chemoattractant Protein-1 (MCP-1) Within the Kidney in Brain Death Donors Predicts Recipient Allograft Function (Oral presentation, American Transplant Congress 2015, Philadelphia PA).
15. Chen J, Zmijewska A, **Mannon RB**. The Forgotten Cell: Renal Fibroblasts are Activated by Anti-Class I MHC Antibody (Oral presentation, American Transplant Congress 2015, Philadelphia PA).
16. **R. Mannon**, P. Stock, A. Mehta, D. Ikle, N. Watson, N. Bridges, M. Robien, K. Newell. Avoidance of CNI and Steroids Using Belatacept – A Preliminary Report of CTOT-16. (Plenary Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
17. M. Seifert, M. Yanik, **R. Mannon**. Predictors of Early Rejection and Allograft Failure in Pediatric Kidney Transplantation: Impact of Histology and Behavior. (Oral Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
18. A. Matas, A. Fieberg, R. Leduc, F. Cosio, R. Gaston, **R. Mannon**, M. Cecka, D. Rush, B. Kasiske, S. Gourishankar, J. Connett, J. Grande. Long-Term Death-Censored Graft Loss in the DeKAF Study. (Oral Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
19. J. Locke, C. Lewis, R. Reed, V. Kumar, D. Sawinski, A. Massie, P. MacLennan, **R. Mannon**, R. Gaston, D. Segev. Obesity Is Associated with Increased Risk of ESRD Among Living Kidney Donors. (Oral Presentation, American Transplant Congress 2016; Boston MA). *Am Jnl Transplantation* 2016; 16 (suppl 3).
20. M. Seifert, S. Goldberg, G. Marusov, S. Jain, D. Brennan, **R.B. Mannon**, D. M. Briscoe. A Novel Microfluidic-Based Platform that Enables Automated, Operator-Independent and Sensitive Monitoring of Renal Allograft Injury in the Clinic. Accepted for oral presentation, International Pediatric Transplant Association, May 2017, Barcelona SP.
21. Zmijewska A, J Chen, J Locke, JW Zmijewski, **RB Mannon**. Release of HMGB1 in serum and urine of brain-death donors is associated with delayed graft function (DGF) of the kidney. (Oral presentation, American Transplant Congress 2017, Chicago IL). *Am Jnl Transplantation* 2017; 17 (suppl 3). Concurrent Session Optimizing Donor Utilization: All Organs. Abstract 458.
22. Seifert, M, Yanik MV, Hauptfeld-Dolejssek V, **Mannon RB**. HLA-C Mismatching and Humoral Alloimmune Responses in Pediatric Kidney Recipients with Subclinical Vascular Injury. (Oral presentation, American Transplant Congress 2017, Chicago IL *Am Jnl Transplantation* 2017; 17 (suppl 3).
23. Stock PG, **Mannon RB**, Armstrong B, Ikle D, Robian M, Morrison Y, Odorico J, Fridell J, Mehta AK, Newell KA. Co-stimulation blockade to minimize and withdraw long term calcineurin inhibitors (CNI) in simultaneous pancreas and kidney transplant (SPK). (Oral presentation, American Transplant Congress 2017, Chicago IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
24. Locke, D. Sawinski, R. Reed, B. Shelton, P. MacLennan, V. Kumar, S. Mehta, **R. Mannon**, R. Gaston, B. Julian, J. Carr, J. Terry, M. Kilgore, A. Massie, D. Segev, C. Lewis. Apolipoprotein L1 & Chronic Kidney Disease Risk in Young Potential Living Kidney Donors. (Oral presentation, American Transplant Congress 2017, Chicago IL). *Am Jnl Transplantation* 2017; 17 (suppl 3).
25. Keslar KS, Gotwald PJ, Xu W, Zmijewska AA, Chen J, Newell KA, Heeger PS, Bromberg JS, **Mannon RB**, Fairchild RL. Unique Gene Expression Signatures in Urine Distinguish BK Virus Nephropathy from Acute Rejection in Kidney Transplant Patients with Graft Dysfunction (Abstract #453). Oral presentation at the 2018 American Transplant Congress, Seattle, WA.
26. Seifert ME, Della Manna D, Liu X, Rosenblum F, Yanik M, Yang E, Pollock J, **Mannon RB**. Molecular Profiling of the Injury-Repair Response in Early Subclinical Inflammation (Abstract #60). Oral presentation at the 2018 American Transplant Congress, Seattle, WA.
27. Zmijewska AA, Zmijewski J, Chen J, **Mannon RB**. Kidney Transplant Rejection is Associated with Robust and Prolonged Bioenergetic Reprogramming and Metabolic Maladaptation. Oral presentation at the 2018 American Transplant Congress, Seattle, WA. *Am J Transplant*. 2018;18 (suppl 3). Concurrent Oral Session Acute Rejection. Abstract 96.

28. Seifert M, Bernard M, **Mannon RB**. Surveillance biopsy: Boon or Bust? Oral Presentation at TTS 2018 27th International Congress of the Transplantation Society Congress, Madrid, SP.
29. Keslar KS, Xu W, Zmijewska AA, Newell KA, Friedewald JJ, Abecassis MI, Heeger PS, Bromberg JS, **Mannon RB**, Fairchild RL. Unique gene expression signatures in urine distinguish T cell mediated acute rejection from BK virus nephropathy in kidney transplant patients. Abstract 429. Oral presentation at the American Transplant Congress, Boston, MA, June 2019.
30. Zmijewska AA, Benavides G, Darley-USmar V, Zmijewski JW, **Mannon RB**. Mitochondrial dysfunction and metabolic reprogramming: critical features of cyclosporine A nephrotoxicity. Abstract 261. Oral presentation at the American Transplant Congress, Boston, MA, June 2019. Am Jnl Transplant 2019; 19 (suppl 3). Concurrent Session: Immunosuppression Preclinical Studies. Abstract 261.
31. Seifert ME, Kasik EP, Bernard M, Agarwal G, Fatima H, Gaston R, Julian B, Kew C, Kumar V, Mehta S, Ong S, Rosenblum F, Towns G, **Mannon RB**. Impact of subclinical BK virus-associated nephropathy in high-risk recipients. Abstract 530. Oral presentation at the American Transplant Congress, Boston, MA, June 2019.
32. Raza S, Agarwal D, Anderson D, Deierhoi D, Fatima H, Hanaway M, Locke J, MacLennan P, Orandi B, Young D, **Mannon R**, Seifert M. Time-zero histology Correlates with Donor Characteristics but Does Not Predict Short-Term Outcomes in Kidney Transplantation. Oral presentation at the American Transplant Congress (Virtual), June 2020.
33. Sheward L, Wedel J, Rodig N, **Mannon R**, Bestard O, Dharnidharka V, Zurakowski D, Kho A, Blydt-Hansen T, Seifert M, Briscoe DM. Automated Monitoring of Four Urinary Biomarkers in Routine Surveillance Identifies Patients at Low and High Risk of Renal Allograft Injury. Oral presentation at the American Transplant Congress (Virtual), June 2020.
34. Lentine K, Alhamad T, Peipert D, Caliskan Y, Concepcion B, Forbes R, Schnitzler M, Zhang z, Chang S, Cooper M, Bloom R, **Mannon R**, Axelrod D. Survey of Clinician Opinions on Use of Organ Transplants from Hepatitis C Virus Positive Donors: Identifying & Overcoming Barriers. Oral presentation at the American Transplant Congress (Virtual), June 2020.
35. Agarwal G, Vinson A, Dai R, French E, Lee S, Olex A, Anzalone A, Madhira V, **Mannon RB**. COVID-19 in Solid Organ Transplantation. Results of the National COVID Cohort Collaborative (N3C). Oral presentation at the American Transplant Congress (Virtual), June 2021. Am J Transplant; 21 (suppl 3). <https://atcmeetingabstracts.com/abstract/covid-19-in-solid-organ-transplantation-sot-results-of-the-national-covid-cohort-collaborative-n3c/>. Accessed June 3, 2021.
36. Reininger K, Onyeaghala G, Anderson-Haag T, Wu B, Guan W, Corr CR, Rimmel R, **Mannon R**, Matas A, Oetting W, Israni A, Stahler P, Jacobson P. Higher Number of Tacrolimus Dose Adjustments and Trough Level Measurements in Kidney Transplant Recipients with CYP3A5*1 Alleles. Oral presentation at the American Transplant Congress (Virtual), June 2021. Am J Transplant; 21 (suppl 3). <https://atcmeetingabstracts.com/abstract/covid-19-in-solid-organ-transplantation-sot-results-of-the-national-covid-cohort-collaborative-n3c/>. Accessed June 3, 2021.
37. Dorr CR, Guo B, Wu B, Abrahante J, Schladt D, Rimmel R, Guan W, Muthusamy A, Onyeaghala G, Pankratz N, Matas A, **Mannon R**, Oetting W, Jacobson P, Israni AK. Extreme Phenotype Sampling and Next Generation Sequencing to Identify Genetic Variants Associated with Tacrolimus Metabolism in African American Kidney Transplant Recipients. Oral presentation at the American Transplant Congress (Virtual), June 2021. Am J Transplant; 21 (suppl 3). <https://atcmeetingabstracts.com/abstract/covid-19-in-solid-organ-transplantation-sot-results-of-the-national-covid-cohort-collaborative-n3c/>. Accessed June 3, 2021.
38. Sun J, Kirk GD, Patel R, Madhira V, Olex AL, French E, Islam JY, Franceschini N, Moffitt R, **Mannon RB**. COVID-19 hospitalization among people with HIV or solid organ transplant in the US. Conference on Retroviruses and Opportunistic Infections 2021; virtual. Topics in Antiviral Medicine 2021; 29 (1): 24-25.

Scientific papers presented at national and international meetings (since 2004)

1. "Practical applications of the renal transcriptome". Satellite workshop: Diagnostic applications of microarrays in organ transplantation, 8th Banff Conference on Allograft Pathology, July 2005, Edmonton, CA.
2. "Transcriptional lessons learned from lymphopenic patients" and "Surrogate markers of chronic allograft nephropathy in man", 8th Banff Conference on Allograft Pathology, July 2005, Edmonton, CA.
3. "The highs and lows of post-transplant immunosuppression: The role of BK polyoma viral monitoring". Third International Conference Polyomaviruses and Human Disease, Providence, RI, September, 2005.
4. "Chronic graft injury". The Transplantation Society Key Opinion Leaders Conference, Montreal, Quebec, Canada, April 2007.
5. "EMT-biomarkers, mediators, and mechanisms", "Polyomavirus, tubular epithelial cells and EMT", and "Molecular markers of active rejection". Ninth Banff Conference on Allograft Pathology, La Coruna, Spain, June 2007
6. "Immune-mediated development of Late Transplant Graft Failure". American Association of Immunologists Annual Meeting, San Diego, CA, April 2008
7. "Immune Monitoring to Guide Therapy". ISN/Nexus: Transplantation and the Kidney: New Insights into the Pathogenesis and Management of Chronic Allograft Dysfunction, Rome, Italy, September 2008.

8. "Late kidney allograft loss: what we know about and what we can do about it". Tenth Banff Conference on Allograft Pathology, Banff, Alberta, CA, August 2009.
9. "Predictors of Transplant Vasculopathy and Glomerulopathy". Transplantation Society 1st International Conference on Transplantomics and Biomarkers in Organ Transplantation, San Francisco, CA, February 2010.
10. "CTGF and Other Factors in Fibrosis". Midday Symposium on New Insights in Fibrogenesis and Tissue Injury. American Transplant Congress 2011, Philadelphia, PA.
11. "What's Hot, What's New" Basic Science. American Transplant Congress 2011, Philadelphia, PA.
12. "New Molecules for Fibrosis". 2012 Joint European Society of Transplantation and American Society of Transplantation Meeting on "Transformational Therapies and Diagnostics in Transplantation". Nice, France, October 2012.
13. "Delayed Graft Function". Saudi International Conference on New Frontiers in in Organ Transplantation. Riyadh, Saudi Arabia, March 2013.
14. "Allograft Fibrosis". Saudi International Conference on New Frontiers in in Organ Transplantation. Riyadh, Saudi Arabia, March 2013.
15. "The relationship between interstitial inflammation, interstitial fibrosis, and graft failure: The DEKAF study and beyond". 12th Banff Conference on Allograft Pathology. Comandatuba, Bahia, Brazil, August 2013..
16. "Macrophages as mediators of allograft injury". 12th Banff Conference on Allograft Pathology. Comandatuba, Bahia, Brazil, August 2013.
17. "The role of macrophages in allograft dysfunction and repair". American Society of Nephrology Kidney Week, Atlanta, GA, November 2013.
18. "What do future clinical trials in transplantation look like?" Workshop speaker and facilitator, Transforming Transplantation: The Expert Summit 2013, Madrid, SP, November 2013,
19. "We'll get 'em next year! The Future of transplantation" Speaker, Transplant immunology for the clinician: understanding the game of transplantation pre-meeting symposia, World Transplant Congress, San Francisco, CA, July 2014.
20. "T Cell and B Cell Targeted Immunosuppression in Transplantation". Speaker, Basic Immunology for the Clinician, American Transplant Congress, Philadelphia, PA, May 2015.
21. "T Cell and B Cell Targeted Immunosuppression in Transplantation". Speaker, Basic Immunology for the Clinician, American Transplant Congress, Boston, MA, June 2016.
22. "Chronic Active TCMR: i, iatr, i-IFTA, and the clinical implications." Banff –SCT Joint Scientific Meeting 2017, Barcelona, SP, March 2017.
23. "T Cell and B Cell Targeted Immunosuppression in Transplantation". Speaker, Basic Immunology for the Clinician, American Transplant Congress, Chicago, IL, April 2017.
24. "Update of noninvasive monitoring in kidney transplantation". American Society of Nephrology Kidney Week 2017, New Orleans, LA, November 2017.
25. "Nephrology Quiz and Questionnaire: Transplantation". American Society of Nephrology Kidney Week 2017, New Orleans, LA, November 2017.
26. "Chronic graft rejection: Mechanisms and Emerging Therapies". Speaker, Basic Immunology for the Clinician, American Transplant Congress, Seattle, WA, June 2018.
27. "The Transplant Therapeutics Consortium: Update on Progress and Goals". TTS 2018 27th International Congress of the Transplantation Society.
28. "Nephrology Quiz and Questionnaire: Transplantation". American Society of Nephrology Kidney Week 2018, San Diego, CA, October 2018.
29. "Best of ASN Journals JASN and CJASN: Transplantation" American Society of Nephrology Kidney Week 2018, San Diego, CA, October 2018.
30. "Strategies to Minimize Risks and Consequences of Delayed Graft Function after Transplant". American Society of Nephrology Kidney Week 2018, San Diego, CA, October 2018.
31. "Controversies in Transplantation: Gene Editing in Transplantation" panel discussant. American Transplant Congress 2019, Boston, MA, June 2019.
32. "The DeKAF Experience: Causes of Total-i, i-IFTA, and t-IFTA and Prognosis". Joint Scientific Meeting of the American Society of Histocompatibility and Immunogenetics and Banff Foundation for Allograft Pathology, Pittsburgh, PA, Sept 2019.

Scientific papers presented at local and regional meetings

Not applicable.

Invited workshops, etc. at national postgraduate courses and meetings and at other universities (since 2004)

1. "The allograft biopsy: What are we looking for in 2004?" Transplant Course, National Kidney Foundation, 2004 Clinical Meetings, Chicago, IL.
2. "Immunosuppression in the absence of calcineurin inhibitors". National Kidney Foundation, 2004 Clinical Meetings, Chicago, IL.
3. "Chronic allograft nephropathy"; "Cases in kidney and pancreas transplantation". American Society of Transplantation Fellows Symposium, August 2004, Dallas, TX.
4. "New approaches in the management of diabetes mellitus". American Society of Transplantation 9th Annual Winter Symposium, Banff, Canada, March 2005.
5. "The failing allograft: what's next?" National Kidney Foundation Clinical Meetings 2005, Washington DC, May 2005.
6. "Long term care of the organ transplant recipient". American Society of Transplantation Primary Care Symposium, Philadelphia, PA, June 2005.
7. "Kidney transplantation at the NIH: Trials, outcomes, and cystinosis". Cystinosis Research Conference, July 2005, Salt Lake City, UT.
8. "Chronic allograft nephropathy", "Cases in kidney and pancreas transplantation", and "What's new in immunosuppression". American Society of Transplantation Fellows Symposium, July 2005, Dallas, TX.
9. "Kidney transplantation at the NIH: Trials, outcomes, and cystinosis". Cystinosis Research Conference, July 2005, Salt Lake City, UT.
10. "Funding and grantsmanship in clinical research". American Society of Transplantation Clinical Trials Symposium—Chair and speaker, Rosemont, IL, September 2005.
11. "Maintaining the balance: Customizing immunosuppression to minimize complications", and "Assessing immune function in the post-transplant patient". Advances in Transplantation, Las Vegas, NV, September, 2005.
12. "BK polyomavirus nephropathy (PVN): What have we learned?" American Society of Nephrology Renal Week 2005, Philadelphia, PA, November 2005.
13. "Transplant immunosuppression: What every nephrologist should know". American Society of Nephrology Evening Symposium "Transplantation: Key issues of the general nephrologist", Philadelphia, PA, November 2005.
14. Monitoring and predicting chronic allograft nephropathy: Surrogate Markers in Man". American Society of Transplant Surgeons. Winter Symposium 2006, Scottsdale, AZ, January, 2006.
15. "Transplant immunosuppression: What every nephrologist should know". Renal Week Highlights, American Society of Nephrology, Washington, DC, February 2006.
16. "How to Write a Grant". Canadian Society of Transplantation Training Day. Mont Tremblant, Québec, CA, March 2006.
17. "Kidney Transplantation in 2006". 2nd Annual Transplant Symposium: *Optimizing medical care of the post-kidney transplant recipient*, National Kidney Foundation of the Nation's Capital Transplant Symposium Chair, Washington, DC, June 2006.
18. "Monitoring of immunosuppression and immune activation in the transplant recipient" Transplant Course, National Kidney Foundation, 2006 Clinical Meetings, Chicago, IL, April 2006.
19. "Current status of liver, heart, and lung transplantation". American Society of Transplantation Eastern Regional Meeting, "The continuum of primary care after transplantation", Arlington, VA, May 2006.
20. "Novel approaches to the management of post-transplant diabetes mellitus". World Transplant Congress Postgraduate Course, Boston, MA, July 2006.
21. "Malignancy after Transplant" and "Managing the failing kidney allograft". Contemporary Forums Advances in Transplantation, Washington DC, October 2006.
22. "Chronic graft failure", "Basic immunosuppression", and "The future of clinical transplantation". American Society of Transplantation Fellows Symposium, Tempe, AZ, October 2006.
23. "Malignancy After Solid Organ Transplantation: Prevalence, Surveillance, Prevention, and Impact". American Society of Transplantation Western Regional Meeting, Los Angeles, CA, October 2006.
24. "The Crisis of Chronic Graft Injury: Evaluating Therapeutic Options". 11th Annual Winter Symposium of the American Society of Transplantation, Phoenix, AZ, February 2007.
25. "ASN Highlights 2006: Transplantation". American Society of Nephrology Renal WeekEnd, Mexico City, MX, March 2007.
26. "ASN Highlights 2006: Transplantation". American Society of Nephrology Renal WeekEnd, Chicago, IL, March 2007.
27. "Banff cans CAN in Canada: New definition of chronic transplant failure". National Kidney Foundation 2007 Spring Clinical Meetings, Orlando, FL April 2007.
28. "ASN Highlights 2006: Transplantation". World Congress of Nephrology, Rio Di Janeiro, Brazil April 2007.
29. "Allograft fibrosis: the response to inflammation". American Transplant Congress 2007 Pre-meeting symposia, San Francisco, CA, May 2007.
30. "Chronic graft failure", "Mechanisms of immunosuppression", and "Malignancy after transplantation". American Society of Transplantation Fellows Symposium in Medicine, Dallas, TX, September 2007.

31. "Biomarkers, mediators, and mechanisms of renal disease". Invited lecture. American Society of Nephrology Renal Week 2007, San Francisco, CA, November 2007.
32. "Malignancy after transplantation". Postgraduate education course in kidney transplantation. American Society of Nephrology Renal Week 2007, San Francisco, CA, November 2007.
33. "Expediting the transplant evaluation". Clinical Nephrology Conference. American Society of Nephrology Renal Week 2007, San Francisco, CA, November 2007.
34. "New factors in chronic allograft nephropathy". Clinical Symposium. American Society of Nephrology Renal Week 2007, San Francisco, CA, November 2007.
35. "How to write a grant in transplantation". Canadian Society of Transplantation Training Academy, Mt. Tremblant, Quebec, CA, February 2008.
36. "Advances in renal transplantation". NIDDK Minority Organ and Tissue Donation Program Meeting, Bethesda, MD, April 2008.
37. "How the transplant physician views basic science findings for patient care". American Association of Immunologists Annual Meeting, San Diego, CA, April 2008.
38. "Who do we need on the research team"? Clinical Trials Symposium, American Society of Transplantation, Toronto, Ontario, CA, May 2008.
39. "Allograft fibrosis: the response to inflammation". American Transplant Congress 2008 Pre-meeting symposia, Toronto, Ontario, CA, May 2008.
40. "Chronic graft failure", and "Malignancy after transplantation". American Society of Transplantation Fellows Symposium in Medicine, Dallas, TX, September 2008.
41. "Clinical Transplantation: 2007-2008 Literature Review". Transplantation, The Year in Review, American Society of Transplantation Regional Symposium, San Francisco, CA, September 2008.
42. "Malignancy after transplantation". Postgraduate education course in kidney transplantation. American Society of Nephrology Renal Week 2008, Philadelphia, PA, November 2008.
43. "Allograft fibrosis". 9th Annual Canadian Transplant Forum, Toronto, Ontario, CA, November 2008.
44. "Allograft fibrosis: the response to inflammation". American Transplant Congress 2009 Pre-meeting symposia, Boston, MA, May 2009.
45. "Assays of alloreactivity and peripheral cell function provide a non-invasive method for identifying risk of rejection". Sunrise Symposium, American Transplant Congress 2009, Boston, MA, May 2009.
46. "Malignancy after transplantation". Postgraduate education course in kidney transplantation. American Society of Nephrology Renal Week 2009, San Diego, CA, October 2009.
47. "The role of innate immunity in transplantation" and "Monitoring the immune system: noninvasive methods for identifying risks of rejection". Advances in Transplantation, San Antonio, TX, November 2009.
48. "Complications of Transplantation: Kidney". American Society of Transplantation Annual Scientific Exchange, Orlando, FL, December 2009.
49. "Why do Kidney Allografts Fail? Mechanisms of Chronic Injury". American Society of Transplantation Annual Scientific Exchange, Orlando, FL, December 2009.
50. "Immuno-camouflage of organ allografts". American Society of Transplantation Winter Meeting, Palm Springs, CA, March 2010.
51. "Allograft Fibrosis: An ends to the means". American Transplant Congress, San Diego, CA, April 2010
52. "Donor Specific Antibody as a Surrogate Endpoint". Invited speaker and panelist, FDA Public Workshop "Issues in the Development of Medical Products for the Prophylaxis and/or Treatment of Acute Antibody Mediated Rejection in Kidney Transplant Recipients". Silver Spring, MD, June 2010.
53. "How to Write a Grant". XXIII International Congress of the Transplantation Society, Postgraduate Weekend, Vancouver, British Columbia, Canada, August 2010.
54. "Malignancy after transplantation". Postgraduate education course in kidney transplantation. American Society of Nephrology Renal Week 2010, Denver, CO, November 2010.
55. ASN Renal Weekends 2011. Transplantation. Chicago, IL, March 2011.
56. "Allograft Fibrosis: An Ends to the Means of Injury." Pre-meeting course in Essential Immunology for the Clinician. American Transplant Congress 2011, Philadelphia, PA.
57. "Transplantation Workshop." Cystinosis Research Network Family Conference 2011, San Francisco, CA.
58. Clinicopathologic Conference. American Society of Nephrology Kidney Week 2011, Philadelphia, PA.
59. ASN Kidney Weekends 2012. Transplantation, Washington, DC, April 2012.
60. ASN Kidney Weekends 2012. Transplantation. The Latin American Society for Nephrology and Hypertension Annual Meeting 2012. Cartagena, Columbia, April 2012.
61. "Kidney Transplantation: Reflections on the Past and Present and Speculation for the Future". Nephrology Friday Morning Conference, Duke University Medical Center, Durham NC, May 2012.

62. "Allograft Fibrosis: An Ends to the Means of Injury." Pre-meeting course in Essential Immunology for the Clinician. American Transplant Congress 2012, Boston, MA.
63. "Immune monitoring of the transplant recipient" and "Innate Immunity in Clinical Practice: Ischemia-reperfusion Injury and the Negative Impact on Graft Outcomes". American Society of Transplantation Fellows Meeting in Transplant Medicine, Grapevine TX, September 2012.
64. "Biomarkers: a window into organs and grafts." State of the Art Lecture at the 3rd Annual George P. Noon Conference Management of Organ Failure, December 2012, Houston, TX.
65. ASN Kidney Weekends 2013. Transplantation, Chicago, IL, March 2013.
66. "Essential Immunology for the Clinician". National Kidney Foundation (NKF) 2013 Spring Clinical Meetings (SCM13), Orlando Florida, April 2013.
67. IV Jornadas Internacionales de Nefrología y ASN Highlights 2013: Transplantation, Rosario, Argentina, April 2013.
68. 10th Congresso Mineiro de Nefrologia Highlights ASN 2013: Transplantation, Belo Horizonte, MG, Brazil, May 2013.
69. "Kidney Transplant Outcomes in Cystinosis". US Cystinosis Advisory Board, New Orleans, LA, October 2013.
70. "Is it time to change long-term study designs: What are we evolving to and how will these changes impact our patients, research and programs?" Cutting Edge of Transplantation: Optimizing Long-Term Transplant Survival, Chandler, AZ, February 2014.
71. Moderator, APOL1 and Kidney Disease Workshop. NIDDK/NIH, College Park MD, June 2015.
72. ASN Kidney Week Highlights 2015: Transplantation, Orlando FL; Mexico City MX. June 2015.
73. "Translational studies in late kidney allograft injury". XLIII Curso Anual de Actualización de Nefrología Clínica. Mexico City, MX. June 2015.
74. "Immune Monitoring in 2015 in Solid Organ Transplantation: Is anything prime time?" Transplant Grand Rounds, Baylor Medical Center, Dallas, TX. August 2015.
75. "Late Kidney Allograft Failure: Translational Studies to Improve Long Term Outcomes". Nephrology Research Conference, University of Utah School of Medicine, Salt Lake City, UT, Sept 2015.
76. "Immunosuppression: Basic Strategies, How they Work, and Novel Agents" and "Innate Immunity in Clinical Practice: The Impact of DGF on Outcomes and Potential Therapeutic Targets". American Society of Transplantation Fellows Symposium, September 2015, Grapevine, TX.
77. Plenary Session: ESOT Meets the World. Overview of Transplantation in culturally diverse regions. Discussant representing US and North America. 17th Congress of the European Society of Organ Transplantation. Brussels, Belgium, September 2015.
78. "What are the clinical phenotypes of renal transplant patients with high immunological risk for graft loss". TTS Consensus Conference on Immunosuppression in Transplantation Trials 2015. Arlington, VA, September 2015.
79. "Regulatory Barriers to New Therapy." Mid-day Symposium American Transplant Congress 2016; Boston MA, June 2016.
80. "Transplant Immunology". American Society of Nephrology Board Review Course and Update 2016. Chicago, IL. August 2016.
81. "Transplant Cases and Immunologic Mechanisms". American Society of Nephrology Board Review Course and Update 2016. Chicago, IL. August 2016.
82. American Society of Transplantation Fellows Symposium Faculty and Speaker, Dallas, TX, September 2016.
83. "Late allograft failure: A continuing challenge of kidney transplantation". Johns Hopkins Comprehensive Transplant Center, Baltimore, MD. February 2017.
84. "Late allograft failure: A continuing challenge of kidney transplantation". New York University School of Medicine, New York, NY, April 2017.
85. "Late Kidney Allograft Failure: Antibody and Cellular Mechanisms". Nephrology Grant Rounds, Vanderbilt University, Nashville, TN, September 2017.
86. "The Continuing Challenge: Late Allograft Failure". Transplantation Grand Rounds, Vanderbilt University, Nashville, TN, September 2017.
87. American Society of Transplantation Fellows Symposium Faculty and Speaker, Dallas, TX, September 2017
88. "Precision Medicine to Improve Transplant Outcomes". Canadian National Transplant Research Program 4th Annual Meeting, Mont Tremblant, Quebec, CA. November 2017.
89. "Pre-implantation Kidney Biopsies as a Predictor for Delayed Graft Function". Presented at the Pre-Conference AKI Symposium of 23rd International Conference on Advanced Critical Care Nephrology AKI/CRRT 2018; Changing paradigms in Acute Kidney Injury: From Mechanisms to Management. San Diego, CA, March 2018.
90. "How to Write a Grant". Post-Graduate Course: Academic Survival Kit. TTS 2018 27th International Congress of the Transplantation Society, Madrid, SP.
91. "AKI in kidney transplants: new insights". Presented at the Pre-Conference AKI Symposium of 24th International Conference on Advanced Critical Care Nephrology AKI/CRRT 2019; Changing paradigms in Acute Kidney Injury: From Mechanisms to Management. San Diego, CA, Feb 2019.

92. "What are the Diagnostic Criteria for Chronic Antibody Mediated Rejection?" Presenter and participant in the Transplantation Society Consensus Guidelines for the Diagnosis and Treatment of Anti-Body Mediated Rejection Meeting, Beverly Hills, CA, March 2019.
93. "Antibody mediated rejection—this is how I do it". Panelist, Transplant Immunosuppression 2019, Minneapolis, MN, Sept 2019.
94. "Personalized medicine-use of the lab: Omics". Transplant Immunosuppression 2019, Minneapolis, MN, Sept 2019.
95. "Who does it better? Machine Perfusion in the Kidney", International attendees breakfast facilitator, What are the Next Steps? The Future of Transplant Immunosuppression". American Society of Transplantation Fellows Symposium Faculty and Speaker, Dallas, TX, September 2019
96. "Who does it better? Machine Perfusion in the Kidney". American Society of Transplantation Fellows Virtual Symposium Faculty and Speaker, September 2020.
97. "Professional Development: Negotiations". American Society of Transplantation Fellows Virtual Symposium Faculty and Speaker, September 2020.
98. "Antibody mediated rejection: Consensus on treatment?" State of the Art Session (A kidney for life: a goal for all practitioners) at the Transplantation Society 2020 Meeting (virtual) September 2020.
99. "Delayed graft function after transplant." Workshop Session (What every ID doc should know about) at the Transplantation Society 2020 Meeting (virtual) September 2020.
100. "Challenges to Transplant Therapeutic Development: Past, Present and Future". First annual ImPrec Project Review (virtual), University of Michigan, Ann Arbor, MI, October 2020.
101. "Innovative Approaches to Clinical Trials in Transplantation". Canadian Society of Transplantation Virtual Forum 2020. November 2020.
102. "Goldilocks diagnostics: Too much, too little, just right". Cutting Edge in Transplantation Transplant Summit 2021 (Virtual), American Society of Transplantation, February 2021.
103. Panelist, "Transplant Visionaries Challenge". Cutting Edge in Transplantation Transplant Summit 2021 (Virtual), American Society of Transplantation, February 2021.
104. "Unmet therapeutic needs: What are they and can we find the fixes? Kidney Con 2021, Virtual Meeting, May 2021.
105. "Challenges in Practical Application of Biomarkers in Transplantation". ATC2021 Virtual Connect Meeting. June 2021.
106. "Cystinosis 301" and "Teenager: Transplant and Dialysis". Panelist, Cystinosis Research Network 2021 Virtual Family Conference.
107. "STAR Working Group Primary Alloimmune Responses Meeting Report". Virtual Webinar, September 23, 2021.
108. "Who does it better? Machine Perfusion in the Kidney". American Society of Transplantation Fellows Virtual Symposium Faculty and Speaker, October 2021.
109. "Professional Development: Negotiations". American Society of Transplantation Fellows Virtual Symposium Faculty and Speaker, October 2021.
110. "Post-transplant management: Case Presentations". American Society of Transplantation Fellows Virtual Symposium Faculty and Speaker, October 2021.
111. "Graft is Not Enough: Exploring New Trial Endpoints." American Society of Nephrology Kidney Week 2021 (virtual), November 2021.
112. "The Christopher R. Blagg Endowed Lectureship in Kidney Diseases and Public Policy: Why Everyone is a Stakeholder in Kidney Health Policy" Closing Comments. American Society of Nephrology Kidney Week 2021 (virtual) November 7, 2021.
113. "Does Cellular Rejection Warrant New Therapies". American Society of Nephrology Future of Organ Transplantation Meeting, Cambridge MA, November 2021.
114. "Safe and Effective Therapies for Rejection: Establishing the Burden of Proof". Transplant Summit 2022. Cutting Edge of Transplantation Virtual Meeting. April 4, 2022.

Invited lectures at local and regional courses and meetings (since 2004)

1. "The Impact of BK Polyomavirus Nephropathy (PVN) on Kidney Allograft Survival". Late Allograft Loss Conference sponsored by NIDDK/NIAID, July 2004, Bethesda, MD.
2. "Transplant immunobiology". Foundation for Advancement of Education in the Sciences Immunology 504, Bethesda, MD, March 2005.
3. "Why do kidney grafts fail? Processes beyond acute rejection that threaten the transplanted kidney". 3rd Annual NIDDK Scientific Retreat, Rocky Gap, VA, April 2005.
4. "Overview of Kidney Transplantation". First annual transplant symposium: *New Frontiers in Transplantation: Optimization Strategies*, National Kidney Foundation of the Nation's Capital Transplant Symposium Chair, Washington, DC, June 2005.
5. "Death and destruction: BK polyomavirus nephropathy". 4th Annual NIDDK Scientific Retreat, Rocky Gap, VA, May 2006.

6. "Advances in renal transplantation". NIDDK Minority Organ and Tissue Donation Program Meeting, Bethesda, MD, April 2008.
7. "Allograft Fibrosis". Children's Hospital Division of Nephrology Research Conference, Birmingham, AL, October 2008.
8. "Immunosuppressive Monitoring in Solid Organ Transplantation: Multiple Agents, Multiple Issues". Clinical Mass Spectrometry User Meeting and Workshop, University of Alabama at Birmingham, Birmingham, AL, May 2009.
9. "Allograft Fibrosis: Innate and Adaptive Mechanisms of Chronic Kidney Injury". Department of Medicine Grand Rounds, University of Alabama at Birmingham, Birmingham, AL, August 2010.
10. "Post-transplant complications". Alabama Kidney Foundation Patient Conference, Birmingham, AL, November 2010.
11. "Late Kidney Allograft Failure: Antibody, cells and more. Core Concepts in Kidney Research Spring Seminar Series of the Nephrology Research and Training Center, University of Alabama at Birmingham, Birmingham, AL June 2017.
12. "A not so basic career". Presented at the summer speaker's series, PRedOctoral PhD and MD research training in TEams (PROmoTE) R25 training program. University of Alabama at Birmingham, Birmingham AL. June 2019.
13. "Solid Organ Transplantation: Adapting Practice to the SARS-COV2 Pandemic". Department of Medicine Grand Rounds, University of Nebraska Medical Center, Omaha, NE, June 12, 2020.
14. "Non-infectious Complications After Kidney Transplantation". Nephrology Fellows Core Curriculum, University of Nebraska Medical Center Division of Nephrology. October 5, 2020.
15. "Personalized Medicine in Transplantation: Reality versus Fiction. Pulmonary, Critical Care, Sleep and Allergy, Immunology Grand Rounds. October 15, 2020.
16. "Putting the **Me** in **Medicine**: Personalized Health Care in Kidney Transplantation". New York Society of Nephrology Virtual Series, April 11, 2022.
17. "Why do kidney allografts fail? Translational approaches to the Pathogenesis of Calcineurin Inhibitor Injury". Research Seminar, Department of Cellular and Integrative Physiology, UNMC, Omaha, NE. May 6, 2022.

MISCELLANEOUS:

Films, educational tapes, syllabi, software packages and courses developed, etc.

1. American Society of Transplant Surgeons Academic Universe Slide Series 2010; Pathological Analysis of Acute and Chronic Kidney Allograft Injury.
2. American Society of Transplantation Timely Topics in Transplantation Webcast 2012; ATC Highlights Basic and Translational Medicine.
3. Podcast Monthly, American Journal of Transplantation, Highlights of the Month, speaker. June 2019-present.
4. American Society of Nephrology Webinar: Challenges in Kidney Transplant in the COVID-19 Pandemic: Implications for Patients and Referring Providers; Organizer and Presenter, April 23, 2020.
5. American Society of Nephrology COVID-19 Taskforce Nephrology Toolkit: Co-Author, Transplantation, July 2020.
6. "STAR Working Group Primary Alloimmune Responses Meeting Report". Virtual Webinar, September 23, 2021.
7. NephSIM Nephrons virtual teaching program in Nephrology. Nov 2020-December 2021.
8. American Journal of Transplantation Journal Club Miniseries on T Cell Mediated Rejection. March-April 2022.

Presentations at Federal Agencies

1. "Pre-clinical models of chronic allograft injury". U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Silver Spring, MD, August 2009.
2. "General review of chronic inflammation in renal allografts". U.S. Food and Drug Administration (FDA) Meeting on Clinical Trials Endpoints, Silver Spring, MD, September 2012.
3. "AST Perspective on Generic Immunosuppression." FDA – AST – ASTS Immunosuppressant Drug meeting, October 22, 2012, Silver Spring, MD.
4. "The critical need for novel therapeutics and interventions in solid organ transplantation.". FDA Public Hearing February 4, 2014, Silver Spring, MD.
5. "Unmet Medical Need In Kidney Transplant Recipients – The Causes of Long Term Graft Loss". Surrogate Endpoints in Clinical Trials in Kidney Transplantation. FDA Public Workshop, Arlington, VA, September 2015.
6. Kidney Innovation Summit, invited participant, Department of Veterans Affairs and VA Center for Innovation, Washington, DC, February 2017.
7. "New Developments in Kidney Transplantation In the Current Decade". Antibody Mediated Rejection in Kidney Transplantation. FDA Public Workshop, Silver Spring, MD, April 2017.
8. "A Call to Action: Unmet Needs in Transplantation. The Genesis of the Transplant Therapeutics Consortium (TTC), A Public Private Partnership". FDA Public Workshop Evidenced Based Treatment Decision in Transplantation: The Right Dose and Regimen for the Right Patient", Silver Spring, MD, September 2018

9. "Genomic SNPs – Biomarkers for Assessing Alloimmune Risk". FDA Public Workshop Evidenced Based Treatment Decision in Transplantation: The Right Dose and Regimen for the Right Patient", Silver Spring, MD, September 2018.
10. "Development of a Urine Gene Expression Signature to Detect Acute T Cell Mediated Kidney Allograft Rejection". FDA Public Workshop Evidenced Based Treatment Decision in Transplantation: The Right Dose and Regimen for the Right Patient", Silver Spring, MD, September 2018.